SIGNALS ON ENDOTHELIUM FOR LYMPHOCYTE RECIRCULATION AND LEUKOCYTE EMIGRATION: THE AREA CODE PARADIGM

TIMOTHY A. SPRINGER

The Center for Blood Research, Harvard Medical School, Boston, Massachusetts

I. INTRODUCTION

The circulatory and migratory properties of white blood cells have evolved to allow efficient surveillance of tissues for infectious pathogens and rapid accumulation at sites of injury and infection. Lymphocytes continually patrol the body for foreign antigen by recirculating from blood, through tissue, into lymph, and back to blood. Lymphocytes acquire a predilection, based on the environment in which they first encounter foreign antigen, to home to or recirculate through that same environment (Cahill et al., 1977, 1979). Granolucytes and monocytes cannot recirculate, but emigrate from the bloodstream in response to molecular changes on the surface of blood vessels that signal injury or infection. Lymphocytes can similarly accumulate in response to inflammatory stimuli. The nature of the inflammatory stimulus determines whether lymphocytes, monocytes, neutrophils, or eosinophils predominate, and thus exercises specificity in the molecular signals or "area codes" that are displayed on endothelium and control the traffic of particular leukocyte classes.

Recent findings show that the traffic signals for lymphocyte recirculation and for neutrophil and monocyte localization in inflammation are strikingly similar at the molecular level. These "traffic signal" or "area code" molecules are displayed together on endothelium but act on leukocytes in a sequence that was first defined for neutrophils and appears to hold true with slight modification for lymphocyte homing as well (Fig. 1). The selectin or green light allows cells to tether and roll, the chemoattractant or yellow light tells cells to activate integrin adhesiveness and put on the brakes, and

The Harvey Lectures, Series 89, pages 53–103
© 1995 Wiley-Liss, Inc.



Fig. 1. Three sequential steps provide the traffic signals that regulate leukocyte localization in the vasculature. Selectin molecules that bind carbohydrate ligands, often displayed on mucinlike molecules, are responsible for the initial tethering of a flowing leukocyte to the vessel wall and labile, rolling adhesions (the green light). Tethering brings leukocytes into proximity with chemoattractants that are displayed on or released from the endothelial lining of the vessel wall. Chemoattractants bind to receptors that span the membrane seven times on the surface of leukocytes. These couple to G proteins, which transduce signals that activate integrin adhesiveness (the yellow light). The integrins can then bind to immunoglobulin superfamily (IgSF) members on the endothelium, increasing adhesiveness and resulting in arrest of the rolling leukocyte (the red light). Following directional cues from chemoattractants and using integrins for traction, leukocytes then cross the endothelial lining of the blood vessel and enter the tissue.

the Ig family member or red light binds integrins and causes cells to come to a full stop. These three steps, with multiple molecular choices at each step, provide great combinatorial diversity in signals. Accordingly, the selective responses of different leukocyte classes to inflammatory agents, as well as the preferential recirculation patterns of distinct lymphocyte subpopulations, can be explained by their distinct receptivity to combinations of molecular signals. Following an overview of leukocytes and endothelium, and of the molecules important in their interactions, I will review the traffic signals that enable selective emigratory behavior of monocytes and neutrophils, and then elaborate how a paradigm of three or four sequential signals can be extended to lymphocyte recirculation. This review updates and extends about twofold a previous one (Springer, 1994). For recent reviews see Carlos and Harlan, 1994; Granger and Kubes, 1994; Picker and Butcher, 1992; Lasky, 1992; Bevilacqua and Nelson, 1993; Bevilacqua, 1993; Butcher, 1991; Baggiolini et al., 1994; Miller and Krangel, 1992; Shimizu et al., 1992; Zimmerman et al., 1992; Harlan et al., 1992; Mackay, 1992, 1993; McEver, 1991; Rosen, 1993; Diamond and Springer, 1994.

II. The Function of Leukocyte Classes Correlates With Circulatory Behavior

Neutrophilic granulocytes are among the most abundant leukocytes in the bloodstream, and the first to appear at sites of bacterial infection or injury. Neutrophils are produced at the prodigious rate of 10^9 cells/kg body weight each day in the bone marrow, and have a half-life in the circulation of 7 hours. Their lifespan after extravasation is hours or less (Cline, 1975). Their primary function is to phagocytose and eliminate foreign microorganisms and damaged tissue.

Monocytes are far less numerous in the blood than neutrophils; their half-life there is about 24 hours (Issekutz and Issekutz, 1993). Like neutrophils, they are phagocytic and accumulate in response to traumatic injury or bacterial infection; however, monocytes differ from neutrophils in that they accumulate at sites where T lymphocytes have recognized antigen, as in delayed-type hypersensitivity reactions and graft rejection. Monocytes are important effector cells in antigen-specific T cell immunity, are activated by T cell products such as γ-interferon, and can organize around parasites into protective structures called granulomas. After extravasation, monocytes may also differentiate into longer-lived tissue macrophages or mononuclear

phagocytes such as the Kupffer cells of the liver, which have a half-life of weeks to months.

In contrast to the neutrophil and monocyte, a lymphocyte may emigrate and recirculate many thousands of times during its life history. Recirculation of lymphocytes correlates with their role as antigen receptor–bearing surveillance cells. Lymphocytes function as the reservoir of "immunological memory," and recirculate through tissues to provide systemic memory. Few of the body's lymphocytes are present at any one time in the bloodstream, where their half-life is 2 hours. Distinct subsets of lymphocytes extravasate through the microvasculature in tissues such as skin and gut, and through specialized high endothelial venules (HEV) in lymphoid organs (Cahill et al., 1977; Mackay, 1992; Picker and Butcher, 1992). After migrating through tissue, lymphocytes find their way into the lymphatics. They percolate through draining lymph nodes in the lymphatic system, and finally enter the thoracic duct, through which they return to the bloodstream. This journey is completed roughly every 1 to 2 days.

III. Endothelium

By displaying specific signals, the endothelium is the most active player in controlling leukocyte traffic. Vascular endothelium is diversified at a number of levels. Large vessels differ from small vessels and capillaries, venular endothelium differs from arterial endothelium, and endothelial phenotype varies between tissues. The preferential migration of leukocytes from postcapillary venules may be related to factors such as shear stress, which is lower there and hence more favorable for leukocyte attachment than in capillaries or arterioles, or to events that occur when leukocytes pass through capillaries. However, when flow is controlled so that shear stress is equivalent in arterioles and venules (Ley and Gaehtgens, 1991), or when the direction of blood flow is reversed (Nazziola and House, 1992), attachment and emigration is far greater from venules, suggesting molecular differences in their endothelial surfaces. In agreement with this, P-selectin is much more abundant on postcapillary venules than on large vessels, arterioles, or capillaries (McEver et al., 1989), and induction of E-selectin and vascular cell adhesion molecule-1 (VCAM-1) expression in inflammation is most prominent on postcapillary venules (Bevilacqua, 1993). The mucinlike CD34 molecule is well expressed on capillaries and is absent from most large vessels (Fina et al., 1990), while CD36 is expressed on microvascular but not large

vessel endothelium (Swerlick et al., 1992). The extracellular matrix may exert an influence on endothelial differentiation, as exemplified by modulation of adhesiveness (Zhu et al., 1991). The high endothelium of lymphoid tissue, which expresses addressins for lymphocyte recirculation, is one of the most dramatic examples of endothelial specialization (Picker and Butcher, 1992).

Inflammatory cytokines dramatically and selectively modulate the transcription and expression of adhesion molecules and chemoattractants in endothelial cells (Pober and Cotran, 1990). Tumor necrosis factor (TNF) and interleukin-1 (IL-1) increase adhesiveness of endothelium for both neutrophils and lymphocytes and induce intercellular adhesion molecule-1 (ICAM-1), E-selectin, and VCAM-1. IL-4, synergistically with other cytokines, increases adhesion of lymphocytes and induces VCAM-1 (Thornhill et al., 1991; Masinovsky et al., 1990). It is likely that the precise mixture of chemoattractants and cytokines produced at inflammatory sites in vivo determines which types of leukocytes emigrate. Thus, injection into skin of IL-1α induces emigration of neutrophils and monocytes; as do lipopolysaccharide (LPS) and TNF-α, but with more prolonged emigration of the monocytes. IFN-γ induces emigration of monocytes but not neutrophils (Issekutz and Issekutz, 1993). IFN-γ and TNF-α, but not IL-1α or LPS recruit lymphocytes, and IL-4 is ineffective by itself but synergizes with TNF (Colditz and Watson, 1992; Briscoe et al., 1992; Issekutz et al., 1988).

Acting more quickly than cytokines, vasoactive substances such as histamine and thrombin modulate endothelial function in seconds or minutes. They induce secretion of the storage granules of endothelial cells and platelets. Furthermore, they dilate arterioles, increase plasma leakage, and raise the hematocrit within microvessels; they thereby alter the rheology of blood so as to increase the collision of leukocytes with the vessel wall (Schmid-Schönbein et al., 1980). Furthermore, arteriolar dilation and the ensuing increased blood flow in inflammatory sites are responsible for two of the cardinal signs of inflammation, rubor (redness) and calor (heat), and greatly enhance the discharge and the accumulation of leukocytes.

IV. Area Code Molecules

A. *Selectins*

Multiple protein families, each with a distinct function, provide the traffic signals for leukocytes. The selectin family of adhesion molecules (Fig. 2) has a N-terminal domain homologous to Ca^{2+}-dependent lectins (Springer,

1990a; McEver, 1991; Lasky et al., 1992; Rosen, 1993; Bevilacqua, 1993). The name selectin capitalizes on the derivation of "lectin" and "select" from the same Latin root, meaning to separate by picking out. Selectins are limited in expression to cells of the vasculature (Fig. 2). L-selectin is expressed on all circulating leukocytes, except for a subpopulation of lymphocytes (Gallatin et al., 1983; Kansas et al., 1985; Lewinsohn et al., 1987). P-selectin is stored preformed in the Weibel-Palade bodies of endothelial cells and the α-granules of platelets. In response to mediators of acute inflammation such as thrombin or histamine, P-selectin is rapidly mobilized to the plasma membrane to bind neutrophils and monocytes (Larsen et al., 1989b; Geng et al., 1990; McEver et al., 1989). E-selectin is induced on vascular endothelial cells by cytokines such as IL-1, LPS, or TNF and requires *de novo* mRNA and protein synthesis (Bevilacqua et al., 1987).

B. Carbohydrates and Mucin-Like Molecules

All selectins appear to recognize a sialylated carbohydrate determinant on their counter-receptors (Bevilacqua and Nelson, 1993; Lasky, 1992; Rosen, 1993). E-selectin and P-selectin recognize carbohydrate structures that are distinct, but are both closely related to the tetrasaccharide sialyl Lewis^x and its isomer sialyl Lewis^a (Fig. 2). The actual ligand structures for E- and P-selectin are more complex than sialyl Lewis^a or ^{x}, as shown by display of the ligand for E-selectin but not P-selectin on fucosyl transferase-transfected cells that express sialyl Lewis^x (Larsen et al., 1992). The affinity of E-selectin for soluble sialyl Lewis^x or ^{a} is quite low, with K_d = 0.2–0.8 mM (Nelson et al., 1993), suggesting that a higher affinity ligand may yet remain to be identified. P-selectin is specific for carbohydrate displayed on the P-selectin glycoprotein ligand (PSGL-1), suggesting either that PSGL-1 expresses a specific carbohydrate structure or that PSGL-1 protein forms part of the ligand binding site (Moore et al., 1992). The affinity of P-selectin for PSGL-1 is high with a K_d = 70 nM (Ushiyama et al., 1993). Structure-function studies suggest that the Ca^{2+}-binding site and a cluster of basic residues on E-selectin coordinate with the fucosyl and sialic acid carboxylate moieties, respectively, of sialyl Lewis^x (Erbe et al., 1992; Graves et al., 1994).

The carbohydrate ligands for L- and P-selectin are O-linked to specific mucinlike molecules. Mucins are serine- and threonine-rich proteins that are heavily O-glycosylated and have an extended structure. L-selectin recognizes at least two mucins in HEV (Fig. 3), glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), which is secreted (Lasky et al., 1992),



Fig. 2. Selectins and their ligands. The selectins are shown to scale, based on electron micrographs of P-selectin (Ushiyama et al., 1993), the X-ray structure of E-selectin lectin and EGF domains (Graves et al., 1994), and estimates of the sizes of the short consensus repeats (SCR) (Springer, 1990a). P-selectin is shown palmitylated on a transmembrane cysteine (Fujimoto et al., 1993). The carbohydrates are not to scale. Sialyl Lewis^a and ^{x} contain Galβ1-3(Fucα1-4)GlcNAc and Galβ1-4(Fucα1-3)GlcNAc linkages, respectively.



Fig. 3. Mucinlike carriers of selectin ligands. The GlyCAM (Lasky et al., 1992) and CD34 (Simmons et al., 1992; Baumhueter et al., 1993) molecules synthesized by peripheral lymph node HEV, and MAdCAM-1 molecule synthesized by mucosal HEV (see Fig. 5), bear O-linked carbohydrates that bind to L-selectin. CD34 has a globular domain that may be Ig-like (Barclay et al., 1993) and is resistant to O-glycoprotease (Sutherland et al., 1992). The PSGL-1 molecule on neutrophils bears O-linked carbohydrates that bind to P-selectin (Norgard et al., 1993; Sako et al., 1993). A cysteine in the transmembrane region is predicted to be palmitylated. O-linked sites and N-linked sites are shown as bars and lollipops, respectively. The length of the mucinlike domains, and the percentage of serines and threonines that are O-glycosylated, are proportioned to measurements for CD43 (45 nm per 224 amino acids and 75–90% of O-glycosylation) (Cyster et al., 1991).

and CD34, which is on the cell surface (Baumhueter et al., 1993). The carbohydrate ligand for L-selectin is related to sialyl Lewis a and x (Foxall et al., 1992; Berg et al., 1992), contains sialic acid and sulfate, and is O-linked to mucinlike structures of HEV (Rosen, 1993). Structural studies on the carbohydrates of GlyCAM-1 show that 6′-sulfated sialyl Lewis x (Fig. 2) is a major oligosaccharide capping group, and is a candidate for the ligand structure (Hemmerich and Rosen, 1994).

The mucinlike P-selectin glycoprotein ligand (PSGL-1) is a disulfide-linked dimer of 120-kd subunits (Moore et al., 1992) that is sensitive to O-glycoprotease, which selectively cleaves mucinlike domains (Steininger et al., 1992; Norgard et al., 1993). PSGL-1 (Fig. 3) was isolated by screening for complementary DNA (cDNA) that expressed ligand activity (Sako et al., 1993). COS cells must be transfected both with the PSGL-1 cDNA and α-3/4-fucosyl transferase cDNA to express P-selectin ligand activity. By contast, COS cells cotransfected with cDNA for α-3/4-fucosyl transferase and another mucinlike molecule expressed by neutrophils, CD43, lack P-selectin ligand activity.

C. Function of Selectins and Their Ligands

Selectins mediate functions unique to the vasculature—the tethering of flowing leukocytes to the vessel wall, and formation of labile adhesions with the wall that permit leukocytes subsequently to roll in the direction of flow. One study demonstrated this with purified P-selectin incorporated into supported planar lipid bilayers on one wall of a flow chamber (Lawrence and Springer, 1991). At wall shear stresses within the range of those found in postcapillary venules, neutrophils formed labile attachments to the P-selectin in the bilayer and rolled in response to fluid drag forces. In other studies, intravascular infusion of a soluble L-selectin/IgG chimera inhibited neutrophil rolling attachments in vivo (Ley et al., 1991), as did infusion of anti-L-selectin monoclonal antibodies (von Andrian et al., 1991). More recent studies have shown that neutrophils roll on E-selectin in purified form (Lawrence and Springer, 1993) or on the endothelial cell surface both *in vitro* (Abbassi et al., 1993) and *in vivo* (Olofsson et al., 1994), that monoclonal antibody(s) (mAb) to P-selectin decrease neutrophil rolling *in vivo* (Bienvenu and Granger, 1993), and that neutrophil rolling in the microvasculature of mice genetically deficient in P-selectin is almost completely absent (Mayadas et al., 1993).

P- and L-selectin may cooperate with one another, because inhibition of either almost completely inhibits neutrophil rolling in vivo (Ley et al., 1991;

von Andrian et al., 1991, 1992; Mayadas et al., 1993). E- and L-selectin also appear to cooperate (Kishimoto et al., 1991; Picker et al., 1991b; von Andrian et al., 1993b; Lawrence and Springer, 1993). A class of ligand that is closely associated with L-selectin on the neutrophil surface is required for the initial tethering during flow to E-selectin bilayers, after which another class of ligands that mediates rolling takes over (Lawrence et al., 1994).

Selectins can mediate tethering of a flowing cell in the span of a millisecond. Other adhesion receptors require minutes to develop similar adhesive strength, and do not mediate rolling (Lawrence and Springer, 1991; Chan et al., 1991). It has been hypothesized that selectins differ from other adhesion molecules not in affinity (K_{eq}), but in having much more rapid association (k_{on}) and dissociation (k_{off}) rate constants (Lawrence and Springer, 1993), as has recently been confirmed (Table I). Rolling is intermittent and appears to be mediated by random association and dissociation of selectin-ligand bonds, a small number of which tether a leukocyte to the vessel wall at any one time. A rapid association rate facilitates the initial tethering in flow. A rapid dissociation rate ensures that even with multiple selectin-ligand bonds, it will not take long before the bond that is most upstream randomly dissociates, allowing the cell to roll forward a small distance until it is held by the next most upstream bond (Lawrence and Springer, 1991; Hammer and Apte, 1992).

The elongated molecular structure of selectins and mucins, and their segmental flexibility (Cyster et al., 1991; Ushiyama et al., 1993), are predicted to enhance their accessibility for binding to counter-structures on closely opposed cells (Lawrence and Springer, 1991). P-selectin and PSGL-1 are currently the most elongated adhesion molecules known (Figs. 3 and 4), and could bridge together two cells with plasma membranes about 0.1 μm apart. Expression on cytoplasmic protrusions further enhances accessibility. L-selectin is clustered on microvilli of neutrophils (Picker et al., 1991b; Erlandsen et al., 1993), which project about 0.3 μm above the surface of a cell with a diameter of 7 μm, and contain 90% of the L-selectin (D.F. Bainton, D.A. Hammer, and T.A. Springer, unpublished). In keeping with this topographic distribution, rolling *in vivo* requires the integrity of the L-selectin cytoplasmic domain and is inhibited by cytochalasin B (Kansas et al., 1993). Lymphocytes bind through microvilli to HEV (Van Ewijk et al., 1975; Anderson and Anderson, 1976). Conversely, the mucinlike CD34 molecule (Simmons et al., 1992) is concentrated on filopodia of nonspecialized endothelial cells found in the microvasculature of most tissues (Fina et al., 1990). These filopodia are concentrated near junctions between endothelial

TABLE I. FAST ON AND OFF RATES OF A SELECTIN, AND AFFINITY MODULATION OF AN INTEGRIN

	k_{on} ($M^{-1}sec^{-1}$)	k_{off} (sec^{-1})	K_d (μM)
P-Selectin	1.4×10^{7} [a]	1 [b]	0.07 [c]
LFA-1 low affinity [d]	3×10^{2}	0.03	100
LFA-1 high affinity [e]	ND [f]	ND	0.6

[a] Calculated from $k_{on}=k_{off}/K_d$.
[b] At very low P-selectin densities in lipid bilayers, neutrophils attach transiently, i.e., they subsequently detach rather than roll. Measurements of the cellular dissociation rate suggest that the $t_{1/2}$ for dissociation of a single selectin-ligand bond is about 0.7 sec (R. Alon and T.A. Springer, unpublished).
[c] For binding of monomeric, truncated P-selectin to neutrophils (Ushiyama et al., 1993).
[d] k_{on}, k_{off}, and K_d were measured by competitive inhibition by monomeric, truncated ICAM-1 of binding of Fab to LFA-1 on resting lymphocytes (Lollo et al., 1993).
[e] Same as (d), but for phorbol ester–stimulated lymphocytes. Approximately 20% of the cell surface LFA-1 was in the high-affinity state (Lollo et al., 1993).
[f] ND = not determined.

cells, and electron micrographs of granulocytes binding to the microvasculature in inflammatory sites suggest that the earliest binding event involves these filopodia (Cross and Raine, 1992).

D. Chemoattractants

Chemoattractants are important in activation of integrin adhesiveness, and in directing the migration of leukocytes. In chemotaxis, cells move in the direction of increasing concentration of a chemoattractant, which typically is a soluble molecule that can diffuse away from the site of its production, where its concentration is highest (Wilkinson, 1982; Devreotes and Zigmond, 1988). Leukocytes, which can sense a concentration difference of 1% across their diameter, move steadily in the direction of the chemoattractant. There is much interplay between adhesion molecules and chemoattractants, since adhesion to a surface is required to provide the traction necessary for migration directed by chemoattractants, and chemoattractants can activate adhesiveness.

The alternative mechanism to chemotaxis is haptotaxis. In "haptotaxis," cells migrate to the region of highest adhesiveness (Carter, 1967). Thus, on a gradient of an adhesive ligand affixed to the surface of other cells or to the extracellular matrix, and in the absence of a chemotactic gradient, motile



Fig. 4. Integrins that bind endothelial ligands. **A.** Schematics of representative integrin α and β subunits. The structures of α^L (Larson et al., 1989) and β_2 (Kishimoto et al., 1987) integrin subunits are shown as representative of α^M and α^X or β_1 and β_7, respectively; cysteines are identical, while glycosylation sites vary, but are sparse in the I domain and EF hand repeats. The EF hand repeats are divalent metal-binding motifs that may bind Ca^{2+} or Mg^{2+} (labeled "Me"). A binding site for Mg^{2+} and Mn^{2+}, but not Ca^{2+}, has been identified in the I domain (Michishita et al., 1993). The α^4 integrin subunit has a posttranslational proteolytic cleavage site (Takada et al., 1989). A putative divalent cation binding site has been defined in the conserved domain of the integrin β_3 subunit and is shown for β_2 (Loftus et al., 1990). **B.** Scale model of an integrin, based on electron micrographs of the integrins gpIIbIIIa (Carrell et al., 1985) and VLA-5 ($\alpha^5\beta_1$) (Nermut et al., 1988).

cells will tend to accumulate in the region of highest ligand density. Both chemotaxis and heptotaxis can contribute to cell localization, but haptotaxis has yet to be demonstrated *in vivo*.

Classical leukocyte chemoattractants act broadly, on neutrophils, eosinophils, basophils, and monocytes (Table II). A recently described family of chemoattractive cytokines, termed chemokines, are polypeptides of 70–80 residues and have specificity for leukocyte subsets (Baggiolini et al., 1994; Miller and Krangel, 1992). Two subfamilies of chemokines have been defined by sequence homology and by the sequence around two cysteine residues (Table II). The CXC or α chemokines tend to act on neutrophils and nonhematopoietic cells involved in wound healing, whereas the CC or β chemokines tend to act on monocytes and in some cases on eosinophils and lymphocyte subpopulations.

It has long been debated whether chemoattractants can act in the circulation, where they would be rapidly diluted and swept downstream by blood flow. Tethering and rolling of leukocytes through selectins will enhance exposure to chemoattractants by prolonging contact with the vessel wall. On the other hand, retention of chemoattractants at their site of production by noncovalent interactions with molecules on the vessel wall and within the inflammatory site may also be important. Heparin-binding sites on chemokines provide a mechanism for retention in the extracellular matrix (Huber et al., 1991), for enhancing concentration gradients, and perhaps for presenting chemokines on the endothelium to circulating leukocytes (Rot, 1992; Tanaka et al., 1993).

E. Chemoattractant Receptors

Leukocyte chemoattractant receptors have multiple functions. They not only direct migration, but also activate integrin adhesiveness, and stimulate degranulation, shape change, actin polymerization, and the respiratory burst (Snyderman and Uhing, 1992). Chemoattractant receptors are G protein–coupled receptors that span the membrane seven times. Ligand binding to the seven membrane-spanner is coupled to exchange of GTP for GDP bound to the associated G protein heterotrimer, and results in activation by the G protein α and $\beta\gamma$ subunits of signaling effectors such as phospholipase C-β2 (Wu et al., 1993). This results in release of diacylglycerol and inositol phosphates, and mobilization of Ca^{2+}. Neutrophils and lymphocytes express $G\alpha_{i2}$ and $G\alpha_{i3}$ subunits (Beals et al., 1987; Snyderman and Uhing, 1992). The $G\alpha$ subunits of the α_i class are ADP-ribosylated and irreversibly inacti-

TABLE II. LEUKOCYTE CHEMOATTRACTANTS

Chemoattractant	Origin	Responding cells
Classical chemoattractants[a]		
N-formyl peptides	Bacterial protein processing	Monocyte, neutrophil, eosinophil, basophil
C5a	Complement activation	Monocyte, neutrophil, eosinophil, basophil
Leukotriene B4	Arachidonate metabolism	Monocyte, neutrophil
Platelet activating factor (PAF)	Phosphatidylcholine metabolism	Monocyte, neutrophil, eosinophil
CXC chemokines[b]		
IL-8/NAP-1	T lymphocyte, monocyte, endothelial cell, fibroblast, keratinocyte, chondrocyte, mesothelial cell	Neutrophil, basophil
CTAP-III/β-thromboglobulin/NAP-2	Successive N-terminal cleavage of platelet basic protein released from α-granules	Neutrophil, basophil, fibroblast
gro/MGSA	Fibroblast, melanomas, endothelial cell, monocyte	Neutrophil, melanomas, fibroblast
ENA-78	Epithelium	Neutrophil
CC chemokines[c]		
MCP-1	T lymphocyte, monocyte, fibroblast, endothelial cell, smooth muscle	Monocyte, T lymphocyte subpopulation, basophil
MIP-1α	Monocyte, B and T lymphocyte	Monocyte, T lymphocyte subpopulation, basophil, eosinophil
RANTES	T lymphocyte, platelet	Monocyte, T lymphocyte subpopulation, eosinophil
I-309	T lymphocyte, mast cell	Monocyte

[a]Devreotes and Zigmond, 1988; Snyderman and Uhing, 1992.

[b]Miller and Krangel, 1992; Baggiolini et al., 1994; Bischoff et al., 1993; Kuna et al., 1993; Carr et al., 1994.

[c]Miller and Krangel, 1992; Schall, 1991; Baggiolini et al., 1994; Tanaka et al., 1993; Schall et al., 1990, 1993; Rot et al., 1992; Alam et al., 1992; Taub et al., 1993a; Kameyoshi et al., 1992; Carr et al., 1994.

vated by pertussis toxin. All of the biological effects of leukocyte chemoattractants are inhibited by pertussis toxin. Coupling through $G\alpha_i$ subunits has been confirmed by reconstitution in transfected cells (Wu et al., 1993). The lipid mediators LTB4 and platelet-activating factor (PAF) are as active as formylated bacterial peptides, C5a, and IL-8 in stimulating chemotaxis, but less active in stimulating the respiratory burst and other functions of neutrophils (Snyderman and Uhing, 1992); this correlates with their ability to couple to distinct $G\alpha$ subunits in transfected cells (Amatruda et al., 1993).

Cloning of the receptors for formylated bacterial peptides, C5a, and PAF has shown that they are expressed on both neutrophils and monocytes, whereas the receptor for IL-8 is expressed only on neutrophils (Murphy, 1994). The receptor for monocyte chemoattractant protein-1 (MCP-1) is expressed on monocytic cells but not on neutrophils (Charo et al., 1994). Thus, the specificity of chemoattractants is regulated by the cellular distribution of their receptors.

F. Integrins

Integrins are perhaps the most versatile of the adhesion molecules. Integrin adhesiveness can be rapidly regulated by the cells on which they are expressed. Each integrin contains a noncovalently associated α and β subunit, with characteristic structural motifs (Fig. 4). Five integrins are important in the interaction of leukocytes with endothelial cells. Their cellular distribution, ligand specificity, and structure are summarized in Table III and Figure 4.

G. Activation of Integrins

The adhesiveness of lymphocyte function-associated antigen-1 (LFA-1) and very late antigen (VLA)-4 on T lymphocytes is activated by cross-linking of the antigen receptor and other surface molecules (Springer, 1990a; Shimizu et al., 1992; Diamond and Springer, 1994). Increased adhesiveness occurs within a few minutes, is not accompanied by any change in quantity of surface expression, and appears to result from both conformational changes that increase affinity for ligand and altered interaction with the cytoskeleton (Faull et al., 1994; Ginsberg et al., 1992; Diamond and Springer, 1994). However, it is unlikely that recognition by T cell receptors of antigen on endothelial cells (Pober et al., 1990) is a step in lymphocyte trafficking, because traffic both of lymphocytes that can and those that cannot recognize specific antigen is increased in antigen-induced inflammation. Although

TABLE III. INTEGRINS IN LEUKOCYTE-ENDOTHELIAL INTERACTIONS

Subunits	Names	Distribution	Ligands
Leukocyte Integrins[a]			
$\alpha^L\beta_2$	LFA-1, CD11a/CD18	B and T lymphocytes, monocyte, neutrophil	ICAM-1, ICAM-2, ICAM-3
$\alpha^M\beta_2$	Mac-1, CR3, CD11b/CD18	Monocyte, neutrophil	ICAM-1, iC3b, fibrinogen, factor X
$\alpha^x\beta_2$	p150,95, CR4, CD11c/CD18	Monocyte, neutrophil, eosinophil	iC3b, fibrinogen
α^4 Integrins[b]			
$\alpha^4\beta_1$	VLA-4, CD49d/CD29	B and T lymphocytes, monocyte, neural crest–derived cells, fibroblast, muscle	VCAM-1, fibronectin
$\alpha^4\beta_7$	LPAM-1, CD49d/CD^-	B and T lymphocyte subpopulations	MAdCAM-1, VCAM-1, fibronectin

[a]Springer, 1990a; Kishimoto et al., 1989b.

[b]Springer, 1990a; Hynes, 1992; Holzmann and Weisman, 1989; Hemler, 1990; Bochner et al., 1991; Horgan et al., 1992; Hu et al., 1992; Berlin et al., 1993; Rüegg et al., 1992; Chan et al., 1992.

evidence has been presented that binding of neutrophils to selectins can activate adhesiveness of integrins (Lo et al., 1991), other evidence has failed to confirm this (Lorant et al., 1991; Lawrence and Springer, 1993; T. Diacovo and T.A. Springer, unpublished).

Thus far, the best candidates for activation of integrin adhesiveness within the vasculature are chemoattractants. Adhesiveness of Mac-1 and LFA-1 on neutrophils and monocytes is activated by N-formylated peptide and IL-8 (Lo et al., 1989; Wright and Meyer, 1986; Buyon et al., 1988; Lo et al., 1989; Diamond et al., 1990; Smith et al., 1991). In contrast to LFA-1 on lymphocytes and neutrophils, Mac-1 on neutrophils is increased about 10-fold on the surface by chemoattractant-stimulated fusion of secretory granules with the plasma membrane (Sengelov et al., 1993); however, this is neither sufficient or necessary for increased adhesiveness (Philips et al., 1988; Vedder and Harlan, 1988). The transient nature of the activation of integrin adhesiveness (Dustin and Springer, 1989; Lo et al., 1989) provides a mechanism for de-adhesion, and perhaps for retraction of the trailing edge of a leukocyte from the substrate during cell migration.

Conformational changes in LFA-1 and Mac-1 that are associated with increased adhesiveness are suggested by the reaction of certain mAb and Fab only with these molecules after cellular activation (Pircher et al., 1986; Keizer et al., 1988; Landis et al., 1993; Diamond and Springer, 1993). After chemoattractant activation of neutrophils, saturation binding shows that 10% of the surface Mac-1 molecules express an activation epitope, yet mAb to this epitope completely blocks binding to ligands such as ICAM-1 and fibrinogen. This suggests that ligand binding is mediated by a subpopulation of activated Mac-1 molecules (Diamond and Springer, 1993). The I domain of leukocyte integrins is important in ligand binding (Diamond et al., 1993; Michishita et al., 1993) and expresses activation epitopes (Diamond and Springer, 1993; Landis et al., 1993). Recent measurements of the affinity of cell surface LFA-1 for soluble, monomeric ICAM-1 (Table I) have directly demonstrated that cellular activation increases the affinity of a subpopulation of LFA-1 molecules approximately 200-fold (Lollo et al., 1993).

Surprisingly, in contrast to LFA-1 and Mac-1, the integrin VLA-4 has recently been found to be capable of supporting rolling. Lymphocytes can tether in flow and subsequently roll on VCAM-1. If activated while rolling by phorbol ester or TS2/16 mAb to the β1 subunit, the lymphocytes arrest and develop firm adhesion. Activated lymphocytes tether as efficiently as resting lymphocytes, but do not roll. Fibronectin can support development



Figure 5.

of firm adhesion in static conditions but not tethering or rolling in flow. VCAM-1 is less efficient than selections in mediating tethering and rolling (Alon et al., 1995).

H. IgSF Members on Endothelium as Integrin Ligands

In a paradigm first established with ICAM-1 binding to LFA-1, several different immunoglobulin superfamily (IgSF) members, expressed on endothelium, bind to integrins expressed on leukocytes (Fig. 5). ICAM-1, ICAM-2, and ICAM-3 are products of distinct and homologous genes, and were all initially identified by their ability to interact with LFA-1 (Rothlein et al., 1986; Staunton et al., 1989; deFougerolles and Springer, 1992). ICAM-1 has also been found to bind to Mac-1, through a distinct site in its third Ig domain (Smith et al., 1989; Diamond et al., 1990, 1991) (Fig. 5). Induction of ICAM-1 on endothelium and other cells by inflammatory cytokines may increase cell–cell interactions and leukocyte extravasation at inflammatory sites, whereas constitutive expression of ICAM-2 may be important for leukocyte trafficking in uninflamed tissues, as in lymphocyte recirculation. ICAM-3 is restricted to leukocytes. All three of the ICAMs contribute to antigen-specific interactions, so that inhibition with mAb to all three is required to completely block LFA-1-dependent antigen-specific T cell responses (deFougerolles et al., 1994).

Fig. 5. Ig superfamily adhesion receptors on endothelium, and their integrin-binding sites. Members of the Ig superfamily share the immunoglobulin domain, composed of 90–100 amino acids arranged in a sandwich of two sheets of antiparallel β-strands, which is stabilized by one or (in the N-terminal domain of the molecules shown) two disulfide bonds. The immunoglobulins and T cell receptors are the only known members of this family that undergo somatic diversification. The function of the IgSF in adhesion evolutionarily predates specialization for antigen recognition. The shape and size of the ICAM-1 molecule, with its unpaired Ig domains and bend, was determined by electron microscopy (Staunton et al., 1990; Kirchhausen et al., 1993), as was that of VCAM-1 (Osborn et al., 1994). Immunoglobulin domains are ellipsoids with a length of 4 nm parallel to the β-strands and 2.5 nm in the other dimensions. The mucinlike region of MAdCAM-1 is modeled as described in the legend to Figure 3; N-linked glycosylation sites in the Ig domains of this and the other molecules are not shown. References for structures (in parentheses) and for localization of the domains to which integrins bind (in brackets): ICAM-1 (Simmons et al., 1988; Staunton et al., 1988) [Staunton et al., 1990; Diamond et al., 1991]; ICAM-2 (Staunton et al., 1989); VCAM-1 (Osborn et al., 1989; Polte et al., 1990; Moy et al., 1993) [Osborn et al., 1992, 1994; Vonderheide and Springer, 1992; Vonderheide et al., 1994]; MAdCAM-1 (Briskin et al., 1993).

VCAM-1 is inducible by cytokines on endothelial cells, and on a more restricted subset of nonvascular cells than ICAM-1 (Bevilacqua, 1993). A single VCAM-1 gene gives rise through alternative splicing to a seven-domain isoform, and to a second isoform that contains either six domains or three domains and a glycosyl phosphatidyl inositol membrane anchor (Moy et al., 1993; Terry et al., 1993; Kinashi et al., 1993) (Fig. 5). VCAM-1 is a ligand for the integrin $\alpha^4\beta_1$ (VLA-4) and binds weakly to $\alpha^4\beta_7$ (Elices et al., 1990; Rüegg et al., 1992; Chan et al., 1992). In contrast to the shorter isoforms, the seven-domain isoform of VCAM-1 has two binding sites for VLA-4, in highly homologous domains 1 and 4 (Osborn et al., 1992, 1994; Vonderheide and Springer, 1992; Vonderheide et al., 1994).

An addressin for lymphocyte recirculation to mucosa is expressed on Peyer's patch HEV and on other venules (Streeter et al., 1988a). Now termed mucosal addressin cell adhesion molecule (MAdCAM-1), it contains three Ig-like domains and a mucinlike region interposed between domains 2 and 3 (Briskin et al., 1993) (Fig. 5). MAdCAM-1 binds the integrin $\alpha^4\beta_7$, but not $\alpha^4\beta_1$ (Hu et al., 1992; Berlin et al., 1993). Furthermore, carbohydrates attached to the mucinlike domain of MAdCAM-1 bind L-selectin and mediate lymphocyte rolling (Berg et al., 1993). Thus MAdCAM-1 has a dual function as an integrin and selectin ligand.

I. Other Molecules

CD31 is an IgSF member expressed on leukocytes, platelets, and at cell-cell junctions on endothelium (Muller et al., 1989; Albelda et al., 1990, 1991; Newman et al., 1990; Simmons et al., 1990; Stockinger et al., 1990; Tanaka et al., 1992). CD31 can bind homophilically to itself, and also heterophilically to an uncharacterized counter-receptor. mAb crosslinking of CD31, as with many but not all other lymphocyte surface molecules, can trigger integrin adhesiveness (Tanaka et al., 1992). Interaction between CD31 on endothelial junctions, and CD31 on leukocytes, appears to be required for transmigration, but not for integrin-mediated binding of leukocytes to endothelium (Muller et al., 1993). CD31-CD31 interaction may represent a fourth step in transendothelial migration that overlaps the integrin-mediated step, and may contribute to the maintenance of the permeability barrier function of endothelia during transmigration.

CD44 is a widely distributed molecule in the body that is homologous with cartilage link protein, is extensively alternatively spliced, and can bear heparin sulfate or chondroitin sulfate side chains (Haynes et al., 1991). The

best-understood function of CD44 is as a major surface receptor for hyaluronate (Culty et al., 1990; Aruffo et al., 1990). Alternatively spliced forms of CD44 are important in tumor metastasis (Günthert, 1993), and in localization of antibody-secreting cells (Arch et al., 1992). CD44 (H-CAM, Hermes) was at one time mistakenly thought to be the human equivalent of murine mel-14 (L-selectin). It participates *in vitro* in lymphocyte interaction with HEV and activated endothelium (Jalkanen et al., 1987; Oppenheimer-Marks et al., 1990). However, lack of cell surface CD44 has no effect on lymphocyte recirculation *in vivo* (Camp et al., 1993).

V. Toward a Multistep Model of Neutrophil Emigration in Inflammation

A. Integrins and Selectins

Patients who are genetically deficient in the leukocyte integrins, owing to mutations in the common β_2 integrin CD18 subunit, provided early evidence that adhesion molecules were required for leukocyte extravasation *in vivo* (Anderson and Springer, 1987; Kishimoto et al., 1989b). Leukocyte adhesion deficiency-I (LAD-I) patients have life-threatening bacterial infections, and neutrophils in these patients fail to cross the endothelium and accumulate at inflammatory sites, despite higher than normal levels of neutrophils in the circulation. *In vitro*, LAD-I neutrophils or normal neutrophils treated with mAb to the leukocyte integrins are deficient in binding to and migrating across resting or activated endothelial monolayers (Buchanan et al., 1982; Smith et al., 1988). Even though capable of binding to activated endothelium through selectins, LAD-I neutrophils fail to transmigrate (Smith et al., 1988). mAb to the leukocyte integrin β_2 subunit, and in some cases the integrin α^M subunit, have been found to have profound effects *in vivo* (Harlan et al., 1992). These mAb prevent the neutrophil-mediated injury that occurs when ischemic tissue is re-perfused, and thus can prevent death from shock after blood loss, avert limb necrosis after frostbite or after amputation and replantation, and stop tissue necrosis from myocardial ischemia and reperfusion. mAb to leukocyte integrins and to ICAM-1 can also inhibit lymphocyte- and monocyte-mediated antigen-specific responses *in vivo*, including delayed-type hypersensitivity, granuloma formation, and allograft rejection (Harlan et al., 1992).

Whereas mAb to the leukocyte integrin β_2 subunit blocked accumulation of leukocytes in tissue in response to chemoattractants, and stable adhesion

of leukocytes in the local vasculature, it had no effect on the number of rolling leukocytes on the vessel wall (Arfors et al,. 1987). Furthermore, leukocyte integrins were found to mediate binding of neutrophils to endothelial monolayers in a parallel wall flow chamber at subphysiologic, but not at physiologic shear stresses found in postcapillary venules (Smith et al., 1988; Lawrence et al., 1990).

Parallel studies showed that selectins were required for leukocyte accumulation *in vivo* and acted at an early step. Antagonists of L-selectin and E-selectin inhibit neutrophil and monocyte influx into skin, peritoneal cavity, and lung in response to inflammatory agents (Lewinsohn et al., 1987; Jutila et al., 1988, 1989; Watson et al., 1991; Mulligan et al., 1991). mAb to L-selectin was shown to inhibit neutrophil accumulation on cytokine-stimulated endothelium at physiologic shear stress (Smith et al., 1991). Stimulation of neutrophils with chemoattractants results in shedding of L-selectin into the medium within minutes; the kinetics are similar to those for upregulation of surface expression of the integrin Mac-1. Based on this, and the evidence reviewed above, it was hypothesized that selectins might act at a step prior to integrins (Kishimoto et al., 1989a).

Further studies showed that selectins mediate rolling, and function prior to development of firm adhesion through integrins. At sites of inflammation, leukocytes first attach to the vessel wall in a rolling interaction, then become arrested or firmly adherent at a single location on the vessel wall before diapedesis (Cohnheim, 1889). This process was fully reconstituted with purified components of the endothelial surface (Lawrence and Springer, 1991). At physiologic shear stresses, neutrophils attach to and form labile rolling adhesions on phospholipid bilayers containing purified P-selectin, but not on bilayers containing ICAM-1. Chemoattractants stimulate strong, integrin-mediated adhesion to bilayers containing ICAM-1 under static conditions but not in shear flow. At physiologic shear stresses, if both P-selectin and ICAM-1 are present in the phospholipid bilayer, resting neutrophils attach and roll identically as on bilayers containing P-selectin alone. However, when chemoattractant is added to the buffer flowing through the chamber, the rolling neutrophils arrest, spread, and firmly adhere through the integrin-ICAM-1 interaction. Chemoattractant does not enhance and actually inhibits interactions of neutrophils with bilayers containing P-selectin alone. This shows that purified adhesion molecules and chemoattractants representing the endothelial signals can reproduce the key events in leukocyte localization *in vivo,* and proves that the selectin-mediated step is a

prerequisite for the chemoattractant and integrin-mediated steps (Lawrence and Springer, 1991). Complementary *in vivo* studies showed that mAb to L-selectin, or L-selectin/IgG chimeras, decreased both the number of rolling leukocytes (Ley et al., 1991; von Andrian et al., 1991) and the number of leukocytes that subsequently became firmly adherent, whereas mAb to the β_2 integrin subunit only decreased firm adherence of leukocytes. This suggested that L-selectin acts at a step prior to leukocyte integrins (von Andrian et al., 1991). In static assays, a factor derived from cytokine-stimulated endothelium induced shedding of L-selectin, and if transmigration was blocked with CD18 mAb, induced release of neutrophils from inverted endothelial monolayers. This also suggested that L-selectin acted prior to leukocyte integrin-mediated emigration (Smith et al., 1991). In elegant confirmation of a three-step model in a static assay of neutrophil adhesion to histamine-stimulated endothelium, Lorant and coworkers demonstrated juxtacrine cooperation between P-selectin and PAF (1991). P-selectin tethered neutrophils to endothelium and thereby augmented stimulation by PAF of CD18-dependent neutrophil adhesion. Stimulation of adhesiveness was by PAF and not by P-selectin, as shown with PAF receptor antagonists.

The idea that the carbohydrate ligands of selectins are required for leukocyte emigration *in vivo* has received strong support from studies of two patients who have a genetic defect in the biosynthesis of fucose, and therefore lack the ligands for E-selectin and P-selectin (Etzioni et al., 1992; von Andrian et al., 1993a). The defect, designated LAD-II, has many clinical similarities to LAD-I, including strikingly depressed neutrophil emigration into inflammatory sites.

B. Chemoattractants

Chemoattractants appear to be required for transendothelial migration *in vitro* and *in vivo,* and can induce all steps required for transmigration *in vivo*. Injection of chemoattractants into skin or muscle leads to robust emigration of neutrophils from the vasculature and accumulation at the injection site (Colditz, 1992). Injection of lipopolysaccharide or cytokines that induce IL-8 synthesis also elicits neutrophil emigration. Moreover, mAb to IL-8 markedly inhibits neutrophil emigration into lung and skin in several models of inflammation (Mulligan et al., 1993; Sekido et al., 1993).

The effects of pertussis toxin provide further evidence for the importance of $G\alpha_i$ protein-coupled receptors in leukocyte emigration *in vivo*.

Pretreatment of neutrophils with pertussis toxin inhibits emigration into inflammatory sites (Spangrude et al., 1985; Nourshargh and Williams, 1990).

Chemoattractants impart directionality to leukocyte migration. In contrast to intradermal injection, intravascular injection of IL-8 does not lead to emigration (Hechtman et al., 1991). Cytokine-stimulated endothelial monolayers grown on filters secrete IL-8 into the underlying collagen layer. Neutrophils added to the apical compartment emigrate into the basilar compartment, but not when the IL-8 gradient is disrupted by addition of IL-8 to the apical compartment (Huber et al., 1991). Although IL-8 may act as an adhesion inhibitor in some assays (Gimbrone et al., 1989), the results may be partially attributable to disruption of a gradient of IL-8 on activated endothelial monolayers when exogenous IL-8 is added on the same side as the neutrophils.

Chemoattractants act on the local tissue, as well as on leukocytes. Neutrophil chemoattractants injected into the same skin site hours apart will stimulate neutrophil accumulation the first time, but not the second, whereas a second injection into a distant site will stimulate accumulation. Desensitization occurs for homologous chemoattractants only (Colditz and Movat, 1984; Colditz, 1991). Thus, chemoattractants must act on and homologously desensitize a cell type that is localized in tissue. In some cases this localized cell may be the mast cell. Some chemoattractants stimulate the mast cell (which localizes in tissue adjacent to the vasculature) or its better-studied relative the basophil, to release histamine (Kuna et al., 1993; Bischoff et al., 1993) and TNF (Walsh et al., 1990). Histamine induces P-selectin and TNF induces E-selectin on endothelium. Thus chemoattractants may indirectly increase selectin expression on endothelium, as well as directly activate integrin adhesiveness on leukocytes.

VI. A Three-step Area Code for Signaling Neutrophil and Monocyte Traffic

The above evidence has shown that emigration from the vasculature of neutrophils and monocytes is regulated by at least three distinct molecular signals (Figs. 1 and 6A). A key feature is that selectin–carbohydrate, chemoattractant–receptor, and integrin–Ig family interactions act in sequence, not in parallel. This concept has been confirmed by the observation that inhibition of any one of these steps gives essentially complete, rather than partial, inhibition of neutrophil and monocyte emigration. An important

consequence of a sequence of steps, at any one of which there are choices of multiple receptors or ligands that have distinct distributions on leukocyte subpopulations or endothelium, is that it provides great combinatorial diversity for regulating the selectivity of leukocyte localization *in vivo,* as has been emphasized in several reviews (Butcher, 1991; Shimizu et al., 1992; Lasky, 1992; Zimmerman et al., 1992; Springer, 1994).

"Area code" models for cell localization in the body (Hood et al., 1987; Springer, 1990b) are particularly apt, since it is now known that there are at least three sequential steps. The concepts of area codes and traffic signals can be combined by considering how telephone traffic is routed by digital signals. Each type of leukocyte responds to a particular set of area code signals. Inflammation alters the expression and location of the signals on vascular endothelium. It is as if leukocytes carry "cellular phones." An example of how this model works is shown for the two cell types for which the signals are best understood, neutrophils and monocytes (Fig. 6B). Chemoattractants provide the greatest number of molecular choices (or "digits") and the greatest cellular specificity.

Refinements to the three-step model are in order. First, selectins actually mediate two steps: initial tethering to the vessel wall, and rolling (Fig. 6A), which can be distinguished for E-selectin by dependence on different classes of neutrophil ligands (Lawrence et al., 1994). Thus, selectins can cooperate; some selectin-ligand combinations may be more important in tethering and others in rolling. Second, the steps are overlapping, rather than strictly sequential (Fig. 6A). Although L-selectin is shed from neutrophils soon after activation (Kishimoto et al., 1989a), the kinetics of shedding by neutrophils in whole blood (minutes) are much slower than the transition from rolling to integrin-mediated attachment (msec–sec) (von Andrian et al., 1991). L-selectin is shed more slowly from lymphocytes than from neutrophils (Jung et al., 1988; Spertini et al., 1991a). Furthermore, ligands for P-selectin (Moore et al., 1992) and E-selectin (Lawrence et al., 1994) remain on the neutrophil surface after activation. Thus interactions with selectins will continue after activation of integrins, probably persisting until transendothelial migration is completed. Chemoattractants are required not only for activation of integrin adhesiveness, but also for directional cues during the subsequent step of transendothelial migration. Finally, β_1 integrins that bind to extracellular matrix components are undoubtedly required during migration through the subendothelial basement membrane.



Fig. 6. The three-step area code model. **A.** Selectins, chemoattractants, and integrins act in sequence, with some overlap. **B.** (on facing page). Combinatorial use of different molecules at each step can generate a large number of different area codes, and specificity for distinct leukocyte subpopulations. All of the known selectin and integrin interactions are shown in the hundreds and ones place, respectively; however, only a subset of the chemoattractants is shown in the tens place (see Table I) due to space limitations. The area codes symbolize how specificity for monocytes, neutrophils, or both can be generated at inflammatory sites.

VII. Lymphocyte Recirculation: Distinct Traffic Patterns for Naive and Memory Lymphocytes

Patrolling the body in search of foreign antigen, lymphocytes follow circuits through both nonlymphoid and lymphoid tissues (Fig. 7). The peripheral lymph nodes draining skin and muscle, and the gut-associated lymphoid tissues such as Peyer's patch, differ in the types of antigens to which lymphocytes are exposed. When collected from lymph draining gut or skin, lymphocytes from adult animals, but not newborns, show a twofold or higher preference for recirculating to the type of organ from which they came and therefore reappearing in the draining lymph (Cahill et al., 1977, 1979; Issekutz et al., 1982; Mackay, 1992). This suggests that priming by specific antigen in a particular environment may induce expression of surface receptors that enable preferential recirculation to the type of secondary organ where specific antigen was first encountered. Evidence exists for separate streams of lymphocytes that recirculate through the



Figure 6B

skin, gut, and lung, and that drain into their associated lymphoid tissues (Mackay, 1992; Picker and Butcher, 1992).

Our understanding of the mechanisms of this selectivity has been advanced by the discovery that "naive" and "memory" lymphocytes prefer different recirculation pathways (Mackay et al., 1990). When naive lymphocytes encounter antigen, those lymphocytes with receptors specific for the antigen are stimulated to clonally expand and are converted to memory lymphocytes that have altered expression of adhesion receptors and circulatory patterns. Lymphocytes that emigrate in the hind leg of a sheep through



Fig. 7. Lymphocyte recirculation routes.

"flat" endothelium in the skin and drain through the afferent lymphatics to the popliteal lymph node are all of the memory phenotype. By contrast, lymphocytes in the efferent lymph from the popliteal lymph node, derived mostly from traffic through HEV, are predominantly of the naive phenotype. Thus, at least for peripheral tissues and lymph nodes, memory lymphocytes emigrate preferentially through tissue endothelium, whereas naive lymphocytes enter the lymph node through HEV (Fig. 7). Memory lymphocytes are more sensitive to specific antigen than naive lymphocytes, and thus more able to respond to antigen in peripheral tis-

sues, which are sparser in antigen-presenting cells than lymph nodes (Mackay, 1993).

VIII. Traffic Through HEV

The "high" or cuboidal endothelial cells found in HEV are specialized for emigration of lymphocytes into peripheral lymph nodes that drain skin and into the lymphoid tissues of the mucosa: Peyer's patches, tonsils, and appendix. Emigration into the spleen, by contrast, involves sinusoidal endothelia and molecular mechanisms that are distinct and not yet characterized. About 25% of lymphocytes that circulate through an HEV will bind and emigrate, a much higher percentage than through nonspecialized flat venules (Bjerknes et al., 1986; Woodruff et al., 1987). HEV phenotype is developmentally regulated. The carbohydrate ligands for L-selectin are absent from peripheral lymph node HEV at birth, but are displayed at adult levels by 6 weeks (Picker and Butcher, 1992). If peripheral lymph nodes are deprived of afferent lymph, the HEV convert from a high to a flat-walled endothelial morphology, lose expression of L-selectin ligands, and lose ability to support lymphocyte traffic (Mebius et al., 1991, 1993). Introduction of antigen into the node leads to a full restoration of HEV phenotype and function. Furthermore, intense antigenic stimulation can induce formation of HEV in diverse nonlymphoid tissues (Picker and Butcher, 1992; Mackay et al., 1992a).

A. Molecular Mechanisms Defined by the HEV Binding Assay

When lymphocyte suspensions are overlayed on thin sections cut from frozen lymph nodes, the lymphocytes specifically bind to the morphologically distinct HEV (Stamper and Woodruff, 1976). Specific differences have been demonstrated between binding to peripheral lymph node and Peyer's patch HEV (Butcher et al., 1980; Woodruff et al., 1987). T lymphocytes bind 1.5 times better than B lymphocytes to peripheral lymph node HEV *in vitro,* and show a similar preference to recirculate to this site *in vivo.* B lymphocytes bind 2 to 3 times better to Peyer's patch than to peripheral lymph node HEV and show similar preference in recirculation *in vivo.* These preferences are reflected in the preponderance of T cells in peripheral lymph nodes, and the preponderance of B lymphocytes in Peyer's patch, where they are important in secretion of IgA and IgM into the mucosa (Stevens et al., 1982). Certain lymphoma cells possess marked preference for binding to Peyer's patch or peripheral lymph node HEV *in vitro* (Butcher et al.,

1980), and for metastasis *in vivo* to mucosal or peripheral lymphoid tissue, respectively (Bargatze et al., 1987). Assay of lymphoma cell binding to HEV in the Stamper-Woodruff assay has led to the identification of two important adhesion pathways.

1. Molecules Involved in Binding to Peripheral Node HEV

The L-selectin molecule was initially defined in the mouse with the Mel-14 mAb as a molecule on lymphocytes required for binding to peripheral lymph node, but not Peyer's patch, HEV (Gallatin et al., 1983). Conversely, the MECA-79 carbohydrate antigen was defined with mAb that bound specifically to peripheral lymph node HEV and blocked lymphocyte binding. The isolated MECA-79 antigen, termed the peripheral node addressin (Streeter et al., 1988b), binds to L-selectin on lymphocytes (Berg et al., 1991b). An L-selectin/IgG chimera was also found to specifically bind to HEV in peripheral lymph node and to block lymphocyte binding (Watson et al., 1990). The L-selectin/IgG chimera was used to isolate two distinct mucinlike ligands, GlyCAM-1, which is secreted by HEV (Lasky et al., 1992), and CD34, a surface molecule on HEV (Baumhueter et al., 1993). MECA-79 mAb recognizes a carbohydrate determinant that is expressed on multiple protein species in HEV, including GlyCAM-1 and CD34, and compared to L-selectin recognizes an overlapping but distinct set of glycoproteins (Lasky et al., 1992; Berg et al., 1991b). Sialylation and sulfation of the O-linked side chains of the GlyCAM-1 and CD34 molecules are required for activity in binding to L-selectin (Berg et al., 1991b; Imai et al., 1993; Rosen, 1993). HEV differ from other tissues in carbohydrate processing; GlyCAM-1 and CD34 expressed in transfectants, and CD34 in other vascular endothelia do not bind L-selectin chimera under conditions in which binding to HEV is detectable (Lasky et al., 1992). However, an L-selectin ligand with a presumably lower affinity is certainly present on most endothelia, as shown by L-selectin-dependent rolling *in vivo* and binding *in vitro* (Smith et al., 1991; vonAndrian et al., 1991, 1993b; Ley et al., 1991; Spertini et al., 1991b, 1992; Kansas et al., 1993).

2. Molecules Involved in Binding to Peyer's Patch HEV

Elegant screens for mAb with specificity for Peyer's patch HEV and the ability to block lymphocyte binding to HEV, yielded mAb MECA-367 to the mucosal addressin now termed MAdCAM-1 (Streeter et al., 1988a). MAdCAM-1 is expressed on endothelia in mucosal tissues, not only on

HEV in Peyer's patch, but also on venules in intestinal lamina propria and in the lactating mammary gland (Streeter et al., 1988a; San Gabriel-Masson, 1992). MAdCAM-1 has both IgSF domains and a mucinlike domain (Briskin et al., 1993) (Fig. 5).

Similar elegant screens for mAbs with specificity for lymphoma cells that bound to Peyer's patch HEV and with ability to block binding to HEV in the Stamper-Woodruff assay yielded mAbs to the α^4 subunit of the Peyer's patch homing receptor (Holzmann et al., 1989). The α^4 subunit was found to be associated with a novel β subunit, β_p (Holzmann and Weissman, 1989), which is identical to β_7 (Hu et al., 1992). The integrin $\alpha^4\beta_7$ but not $\alpha^4\beta_1$ binds to Peyer's patch HEV (Hu et al., 1992), and $\alpha^4\beta_7$ binds directly to MAdCAM-1 (Berlin et al., 1993).

B. An Area Code Model for Lymphocyte Migration Through HEV

1. Peripheral Lymph Node HEV

Although the L-selectin–mucin and $\alpha^4\beta_7$–MAdCAM-1 interactions were identified in parallel assays, recent studies suggest that multiple steps are involved in lymphocyte interaction with HEV, and raise the possibility that these interactions may function in distinct, rather than parallel, steps in this process. Soon after its discovery as a peripheral lymph node homing receptor, L-selectin was found to be present on neutrophils and eosinophils as well, and to be important in emigration of at least neutrophils (Lewinsohn et al., 1987). As expected from their strong expression of L-selectin, neutrophils and other leukocytes can bind avidly to HEV in the Stamper-Woodruff assay, yet do not normally home to peripheral lymph nodes *in vivo.* Injection of *E. coli* supernatant induces acute emigration of neutrophils through HEV of the draining lymph node. Thus, signals other than those mediated by L-selectin can regulate the class of leukocyte that homes into a lymph node (Lewinsohn et al., 1987). Although peripheral node HEV is far richer than any other site in the body in expression of the carbohydrate receptor for L-selectin (Imai et al., 1991), this is insufficient to explain the specificity of lymphocyte homing to this organ. The findings suggest that L-selectin is required for lymphocyte emigration through peripheral lymph node HEV, and may help regulate recirculation of the L-selectin$^+$ subset of lymphocytes; however, L-selectin is insufficient to determine the specificity of the cell types that emigrate, and other, currently undefined molecules are required to achieve specificity.

In vivo studies strongly suggest that lymphocyte emigration through HEV is a multistep process that utilizes area code models similar to those of other leukocytes. mAb to L-selectin almost completely blocks emigration of lymphocytes from blood into peripheral lymph nodes (Gallatin et al., 1983; Hamann et al., 1991). However, mAb to the integrin LFA-1 also markedly reduces or almost completely abolishes lymphocyte migration into peripheral lymph nodes (Hamann et al., 1988; Camp et al., 1993). Thus, molecules of steps 1 and 3 are required for homing to peripheral lymph nodes *in vivo*. LFA-1 on blood lymphocytes requires activation for binding to its counter-structures ICAM-1 and ICAM-2 (Springer, 1990a), which are expressed on HEV (Dustin and Springer, 1989; deFougerolles et al., 1991). Binding of L-selectin does not trigger activation of LFA-1, since lymphocytes attach and roll in flow on purified peripheral node addressin identically, whether or not purified ICAM-1 is present on the substrate; an additional stimulus is required before lymphocytes will arrest and strengthen adhesion through LFA-1 (M. Lawrence, E. Berg, E. Butcher, and T.A. Springer, in preparation).

G protein–coupled receptors are required for lymphocyte recirculation and likely provide the signals required to activate the adhesiveness of LFA-1. Pertussis toxin causes lymphocytosis and profoundly depresses lymphocyte recirculation (Wardlaw and Parton, 1983). Murine lymphocytes treated with pertussis toxin *in vitro* and re-infused fail to emigrate into either peripheral lymph nodes or Peyer's patches (Morse and Barron, 1970). This suggests that G protein–coupled receptors of the α_i class are required for lymphocyte emigration through HEV. Results with mice with a transgene for the ADP-ribosylating subunit of pertussis toxin selectively expressed in the T lineage suggest that $G\alpha_i$ proteins are not only required for emigration from the bloodstream, but also for emigration from the thymus (Chaffin et al., 1990; Chaffin and Perlmutter, 1991). Despite lack of emigration, lymphocytes treated with pertussis toxin bind normally to lymph node HEV *in vitro*. These findings provided the basis for an early proposal for a two-step model, in which G protein–coupled receptors function subsequent to binding of lymphocytes to HEV (Spangrude et al., 1984).

Thus, emigration of lymphocytes through peripheral node HEV requires three sequential area code signals that are analogous to those involved in neutrophil emigration from the bloodstream (Fig. 8). Identification of a putative lymphocyte chemoattractant secreted by peripheral lymph node HEV, and a chemoattractant receptor that is predicted to be selectively expressed

on the naive subset of lymphocytes that recirculate through peripheral node HEV, will be a subject of intense research interest in coming years.

2. Peyer's Patch

mAb to L-selectin block 50% of lymphocyte emigration from blood to Peyer's patch and to the remainder of the intestine (Hamann et al., 1991, 1993). This is consistent with the lower level of L-selectin ligand in Peyer's patch HEV than in peripheral lymph node HEV (Watson et al., 1990; Bargatze et al., 1990; Mackay et al., 1992b). mAb to certain epitopes on the integrin α^4 and β_7 subunits block recirculation of lymphocytes to Peyer's patch and intestine about 50%, but have no effect on recirculation to peripheral lymph node; furthermore, mAb specific for the $\alpha^4\beta_7$ complex are just as effective as mAb to α^4 (Hamann et al., 1993). Moreover, recirculation is blocked by mAb to MAdCAM-1 (Streeter et al., 1988a), implicating $\alpha^4\beta_7$ binding to MAdCAM-1 in recirculation to mucosal tissue. mAb to LFA-1 block recirculation to Peyer's patch by 50% to 80% but have no effect on recirculation to the remainder of the intestine (Hamann et al., 1988; Camp et al., 1993). Thus, both LFA-1 and $\alpha^4\beta_7$ contribute to emigration into mucosal lymphoid tissue.

G protein–coupled receptors act subsequent to a rolling interaction in Peyer's patch HEV. In contrast with peripheral lymph nodes, Peyer's patches may be visualized by intravital microscopy (Bjerknes et al., 1986). Normally, lymphocytes roll along Peyer's patch HEV only for a few seconds, then arrest and emigrate. However, prior treatment of lymphocytes with pertussis toxin completely blocks arrest and emigration, and prolongs the rolling indefinitely, so that the lymphocytes pass out of the Peyer's patch rather than emigrate (Bargatze and Butcher, 1993). It remains to be established, but seems likely, that a chemoattractant presented or secreted by Peyer's patch binds to a $G\alpha_i$-coupled receptor on lymphocytes, and activates LFA-1 and $\alpha^4\beta_7$ to mediate arrest and emigration (Fig. 8). Lymphoma cells or lymph node lymphocytes can bind to Peyer's patch HEV or purified MAdCAM-1 without any apparent need for activation; however, activation increases the strength of binding to MAdCAM-1 (Hu et al., 1992; Berlin et al., 1993). The pertussis toxin studies suggest that activation of blood lymphocytes is required for the last step of arrest and emigration (Spangrude et al., 1984; Bargatze and Butcher, 1993). Truncation of the cytoplasmic domain of β_7 greatly decreases binding to HEV. Thus, interactions with the cytoplasmic domain can regulate the avidity of $\alpha^4\beta_7$ for MAdCAM-1 (Crowe



Fig. 8. The three-step or four-step area code paradigm for lymphocytes. For skin and gut, the pathways shown may mediate both recirculation and increased accumulation in inflammation. The novel pathway shown at the bottom may be important when VCAM-1 expression on endothelium is induced by cytokines and may cooperate with the other illustrated pathways. For each organ, the interacting molecules are shown on the top for lymphocytes and on the bottom for endothelia. See text for support for the molecular assignments at each step, based primarily on *in vivo* data.

et al., 1993), similar to regulation through the β_2 integrin subunit cytoplasmic domain of the avidity of LFA-1 for ICAM-1 (Hibbs et al., 1991a,b).

IX. Recirculation of Memory Lymphocytes

A. Distinct Pathways Through Skin and Gut

Memory lymphocytes are imprinted so that they are more likely to return to the type of tissue, such as skin or mucosa, where they first encountered antigen (Cahill et al., 1977, 1979; Mackay, 1992). The surface phenotypes of gut- and skin-homing memory cells are distinct (Mackay et al., 1992b). Furthermore, staining of lymphocyte in sections of skin and gut with mAb shows distinctive expression of adhesion molecules, which may contribute to selective extravasation in these tissues, or to subsequent localization within these tissues in specific anatomic compartments (Table IV).

B. Skin-Homing Lymphocytes

Lymphocytes that extravasate in the skin and appear in afferent lymph have a distinct pattern of expression of adhesion molecules (Mackay et al., 1992b) (Table IV). Furthermore, as shown by staining of tissue sections, T lymphocytes localized in the skin, but not in the gut, express a carbohydrate termed cutaneous lymphocyte associated antigen (CLA) (Picker et al., 1990a). CLA is closely related to sialyl Lewis a and x (Berg et al., 1991a) and is a ligand for E-selectin (Berg et al., 1991c). Binding of a subpopulation of memory lymphocytes that bears CLA to E-selectin may contribute to the tropism of this subset to the skin (Graber et al., 1990; Picker et al., 1991a; Shimizu et al., 1991). E-selectin is induced on dermal endothelial cells in delayed-type hypersensitivity (Cotran et al., 1986) and in chronically inflamed skin (Picker et al., 1991a). Cloned T cells derived from challenged skin express high levels of CLA and bind to E-selectin, whereas T cell clones derived from blood lymphocytes do not (Alon et al., 1994). Both types of clones bind to P-selectin.

C. Gut-Homing Lymphocytes

The most organized lymphoid structures in the wall of the gut are the Peyer's patches, which underlie follicle-associated epithelia that contain M cells, which are specialized for uptake of antigen from the gut lumen. Other lymphocytes localize more diffusely in the lamina propria underlying the digestive epithelium, and in the epithelial layer. Studies on gut-afferent lymph

TABLE IV. NAIVE AND MEMORY LYMPHOCYTE SUBSETS[a]

Molecule	Naive lymphocytes	Memory lymphocytes
CD45RO	Negative	Positive
CD45RA	High	Low
CD2	Low	High
LFA-3	Negative	Positive
L-selectin	Positive	Positive and negative subsets
α^4	Low	High
	Memory lymphocytes subsets	
	Gut-associated	Skin-associated
CLA	Negative	Positive
$\alpha^E\beta_7$ (HML-1)	Positive	Negative
$\alpha^4\beta_7$	High	Low
$\alpha^4\beta_1$	Low	High
α_6	Low	High

[a]References: Mackay et al., 1992b; Schweighoffer et al., 1993; Horgan et al., 1992. For $\alpha^4\beta_7$, see also Kilshaw and Murant, 1991.

reveal the presence of both memory and naive lymphocytes (Mackay et al., 1992b); whether there is differential migration of naive and memory lymphocytes through Peyer's patch HEV and lamina propria postcapillary venules, both of which contribute to gut-afferent lymph (Fig. 7), remains unclear. Gut-homing memory lymphocytes display a surface phenotype distinct from skin-homing lymphocytes (Table IV). When injected into the bloodstream, memory lymphocytes from gut afferent lymph display a strong preference for returning to gut afferent lymph, whereas naive lymphocytes redistribute randomly (Mackay et al., 1992b). Gut afferent memory lymphocytes display an α_4 high, β_1 integrin low phenotype, suggesting they are $\alpha^4\beta_7^+$ (Mackay et al., 1992b), in common with a subpopulation of memory lymphocytes in blood (Schweighoffer et al., 1993). Expression of MAdCAM-1 on both Peyer's patch HEV and postcapillary venules in lamina propria (Streeter et al., 1988a), and 50% inhibition of migration into both Peyer's patch and intestine by mAb to α^4 and β_7 (Hamann et al., 1993) suggests a role for $\alpha^4\beta_7$ interaction with MAdCAM-1 in both sites.

A subpopulation of gut lymphocytes distinct from those in lamina propria localize within the epithelium on the external surface of the basement membrane and express the human mucosal lymphocyte (HML-1) integrin $\alpha^E\beta_7$ (Cerf-Bensussan et al., 1987; Kilshaw and Murant, 1990; Parker et al., 1992). The α^E integrin subunit contains an I domain and a novel proteolytic

cleavage site preceded by a stretch of acidic residues, just N-terminal to the I domain (Shaw et al., 1994). Binding of intraepithelial lymphocytes (IEL) to epithelial cell monolayers *in vitro* is inhibited by mAb to α^E, suggesting that $\alpha^E\beta_7$ may help mediate localization of IEL in epithelia *in vivo* (Cepek et al., 1993). Intraepithelial T lymphocytes may undergo thymus-independent differentiation *in situ* and their recirculation pattern is undefined. HML-1 is expressed on a subpopulation of 2% to 6% of blood T cells, which are in the memory subset and are CLA^- and L-selectin$^-$ (Picker et al., 1990b). Transforming growth factor β (TGF-β), together with mitogen, induces expression of HML-1 on peripheral T cells and increases expression on IEL (Kilshaw and Murant, 1990; Parker et al., 1992). TGF-β also induces switching of B lymphocytes to production of the IgA class of immunoglobulin (Coffman et al., 1989), the predomiannt class secreted in the mucosa. These dual effects on differentiation of mucosal lymphocytes suggest the possibility that TGF-β may be an environment-specific cytokine that imprints lymphocytes, when first exposed to antigen, to recirculate selectively to the gut.

X. Alteration of Lymphocyte Trafficking in Inflammation

Antigen injected into the tissue of sensitized individuals induces localized accumulation of lymphocytes. These lymphocytes, and those accumulating in tissues in autoimmune disease, are almost all memory cells (Pitzalis et al., 1988; Janossy et al., 1989). The phenotype of these cells is quite similar to that of lymphocytes trafficking through these sites under basal conditions. This suggests that the signals for lymphocyte trafficking may be qualitatively the same in the basal and inflammatory states, and are upregulated in inflammation. Accumulation of lymphocytes induced by specific antigen, or by injection of IFN-γ or TNF-α, is significantly inhibited by mAb to either the LFA-1α or the integrin α^4 subunit (Issekutz, 1991, 1992; Chisholm et al., 1993; Yednock et al., 1992; Scheynius et al., 1993). A combination of mAb to LFA-1 and α^4 gives almost complete inhibition of lymphocyte emigration and the resulting induration and plasma leakage (Issekutz, 1993). mAb to E-selectin and VCAM-1 also inhibit lymphocyte accumulation in delayed-type hypersensitivity in skin (Silber et al., 1994). Multiple signals are thus required for augmented trafficking of lymphocytes into skin in inflammation (Fig. 8). Both antigen-responsive and nonreponsive lymphocytes traffic into sites of antigenic stimulation (McCluskey et al., 1963). Antigen-specific lymphocytes may accumulate in the site because stimula-

tion through their antigen receptors increases adhesiveness of integrins and causes them to be retained, whereas nonresponsive lymphocytes more rapidly enter the lymphatics and leave the site.

Since the interaction between VCAM-1 and VLA-4 can mediate both rolling and firm adhesion (Alon et al., 1995), it does not fit neatly into the three-step paradigm established for neutrophils. mAb to LFA-1 or VLA-4 alone do not completely inhibit lymphocyte accumulation in inflammation, and patients with LAD-I show delayed-type hypersensitivity reactions. This suggests that the functions of VLA-4 and LFA-1 are partially overlapping in the step of firm adhesion, but they may also act in series, as in VLA-4-mediated rolling followed by LFA-1-mediated firm adhesion. VLA-4 may act together with selectins to augment T lymphocyte tethering and rolling in the vasculature. All or most memory T lymphocytes lack L-selectin (Kansas et al., 1985; Tedder et al., 1990; Mackay et al., 1992b; Bradley et al., 1992). The CLA^+ subset can bind E-selectin, and T lymphocytes can also bind P-selectin (Moore and Thompson, 1992; Damle et al., 1992). Peripheral blood T lymphocytes are substantially less efficient than neutrophils in tethering in flow to E-selectin and P-selectin (T. Diacovo, R. Alon, T.A. Springer, unpublished); therefore, cooperation of VCAM-1 with E-selectin or P-selectin, or among all three molecules, may be important in enhancing lymphocyte accumulation in inflammation.

Inflammation also affects traffic through HEV. Antigen injected into tissue drains to the regional lymph node, and greatly increases both blood flow to the node and traffic of naive lymphocytes through HEV (Mackay et al., 1992a). Furthermore, memory lymphocytes now appear to enter the node directly; this is associated with induction of VCAM-1 on non-HEV vascular endothelia within the node (Mackay et al., 1992a). Entry is inhibited by mAb to α^4, and this suggests a role for interaction of VCAM-1 with $\alpha^4\beta_1$ (Issekutz, 1991; Mackay et al., 1992a).

Lymphocyte chemoattractants are interesting candidates for the step 2 signal for lymphocyte accumulation at inflammatory sites. Pertussis toxin treatment inhibits lymphocyte emigration in response to antigen in delayed-type hypersensitivity (Spangrude et al., 1985). Identification of lymphocyte chemoattractants has been hampered by the low motility of lymphocytes compared to monocytes or neutrophils (Parrott and Wilkinson, 1981), and the low signal-to-background ratio, typically less than 2, in most chemotaxis assays. Recent interest has focused on chemokines (Table II). A number of chemokines, all of which were isolated based on chemoattractive

activity for neutrophils or monocytes, or by cloning genes of unknown function, have subsequently been tested and found to be chemoattractive for lymphocyte subpopulations (Miller and Krangel, 1992; Baggiolini et al., 1994). These chemokines include IL-8 (Larsen et al., 1989a; but see Kudo et al., 1991; Leonard et al., 1991), RANTES (Schall et al., 1990), MIP-1β (Tanaka et al., 1993), MIP-1α and -β (Taub et al., 1993a; Schall et al., 1993), and IP-10 (Taub et al., 1993b). There are differences among reports in the subsets found to be chemoattracted, and some reports use lymphocytes preactivated by T cell receptor cross-linking, which may be relevant to migration within inflammatory sites, but not to emigration from blood. Of interest, MIP-1β can induce binding of the naive, $CD8^+$ subset to VCAM-1, either in solution or, when immobilized on a substrate, mimic presentation by an endothelial cell surface (Tanaka et al., 1993; Adams et al., 1994); the specific effect is modest, equal to background binding. The RANTES cytokine, by contrast to MIP-1β, selectively attracts the memory T lymphocyte subset (Schall et al., 1990).

Vascular endothelium may function to present chemoattractant to lymphocytes in a functionally relevant way, as well as to provide a permeability barrier that stabilizes the chemoattractant gradient. A transendothelial chemotaxis assay more accurately simulates lymphocyte emigration from the bloodstream than filter chemotaxis assays, and yields signals >10 times background (Carr et al., 1994). Since lymphocytes, responding to specific antigen in tissue, signal emigration of further lymphocytes into the site, a chemoattractant was sought in material secreted by mitogen-stimulated mononuclear cells. Purification to homogeneity guided by the transendothelial lymphocyte chemotaxis assay revealed that MCP-1, previously thought to be solely a monocyte chemoattractant, is a major lymphocyte chemoattractant (Carr et al., 1994). Subsequent studies using the transendothelial chemotaxis assay have confirmed that lymphocytes respond to RANTES and MIP-1α (C-C chemokines), but do not respond to IL-8 or IP-10 (C-X-C chemokines) (Roth et al., 1994). MCP-1, RANTES, and MIP-1α all selectively attract the memory T lymphocyte subset, and both the CD4 and CD8 subsets. All also attract monocytes but not neutrophils, with MCP-1 being more potent than RANTES or MIP-1α as a monocyte chemoattractant. The physiologically relevant transendothelial assay suggests that C-C chemokines tend to attract both monocytes and lymphocytes, in agreement with the longstanding clinical observation that lymphocyte emigration into inflammatory sites is always accompanied by emigration of monocytes. The converse

is not true. Monocytes sometimes emigrate in the absence of lymphocytes, correlating with activity of chemoattractants such as C5a and platelet-aggregating factor (PAF) on monocytes but not on lymphocytes. Teleologically, it is important that monocytes accompany lymphocytes into inflammatory sites in order to present antigen, and to carry out effector functions in which monocytes are activated by T lymphocytes. MCP-1 is abundantly expressed at sites of antigen challenge and autoimmune disease (Leonard and Yoshimura, 1990; Miller and Krangel, 1992; Villiger et al., 1992), and together with MIP-1α and RANTES, is an excellent candidate to provide the step 2 signal required to activate integrin adhesiveness and emigration of both monocytes and lymphocytes *in vivo* (Fig. 8).

The finding that resting T lymphocyte that tether and roll on VCAM-1 can spontaneously arrest and develop firm adhesion on VCAM-1 (Alon et al., 1995) has provocative implications for the multistep model. It suggests that the VLA-4–VCAM-1 interaction can not only mediate the steps of rolling and firm adhesion, but may also short-circuit the step of stimulation by chemoattractants of firm adhesion through integrins. This is intriguing, since although a twofold stimulation of adhesiveness of VLA-4 to VCAM-1 has been demonstrated by MIP-1β in one system (Tanaka et al., 1993), with the chemoattractant that is most effective in eliciting transendothelial chemotaxis of T lymphocytes, MCP-1, it is difficult to detect stimulation of integrin adhesiveness on lymphocytes (M.W. Carr and T.A. Springer, unpublished). Therefore, an alternative pathway may exist in which VCAM-1 can mediate both tethering and arrest of lymphocytes, perhaps in cooperation with other endothelial molecules, prior to stimulation by chemoattractants. After arrest, chemoattractants would guide transendothelial migration, and perhaps stimulate further increases in the adhesiveness of the integrins VLA-4 and LFA-1 important in migration across the endothelium and basement membrane.

XI. Concluding Remarks

A three-step or area code model of leukocyte emigration from the bloodstream, established and validated *in vitro* and *in vivo* with neutrophils (Figs. 1 and 6B), appears extendible with only slight modification to all subclasses of leukocytes including lymphocytes (Fig. 8). Multiple adhesion and chemoattractant receptors are used combinatorially in a series of steps that enable leukocytes to progress from initial tethering in flow to firm adhesion

and emigration. The distinct distribution of receptors on leukocyte subsets for signals that are displayed on endothelium regulates selection of the subclasses of leukocytes that emigrate at inflammatory sites, and the distinctive recirculation behavior of lymphocyte subsets.

Many important developments await. Strong evidence suggests that G protein–coupled receptors are required for lymphocyte recirculation, but many of the putative lymphocyte chemoattractants specific to HEV, mucosa, and skin, and the receptors for these chemoattractants on lymphocytes, remain to be identified. Specific mucinlike molecules have recently emerged that present carbohydrate ligands to selectins. Are there similar mucinlike molecules on lymphocytes that present carbohydrates to P-selectin or E-selectin, and do these differ from the PSGL-1 molecule on neutrophils? It is likely that endothelial cells express molecules that retain chemoattractants on the luminal surface, preventing them from being washed away by blood flow, as already suggested for MIP-1β and IL-8. Are these molecules specifically regulated? The mucinlike ligands of selectins have many features such as extended structure, sulfation, and negative charge in common with proteoglycans, and thus might have a second function of binding chemokines through their heparin-binding sites and presenting them to leukocytes. Presenting molecules might be required not only to prevent chemoattractants from being washed away by blood flow, but also might be required for maximal chemoattractant activity, analogous to proteoglycans that must bind fibroblast growth factor to enable signaling through a second receptor molecule. It will be interesting to determine whether chemoattractant receptors on leukocytes couple to distinct G proteins and signaling effectors. This would result in differences between chemoattractants' ability to upregulate adhesiveness of two integrins such as LFA-1 and VLA-4 expressed on the same cell. Finally, after the area code is dialed and cells emigrate across the endothelium, much remains to be learned about the "7-digit code" that regulates leukocyte migration and localization within specific anatomic compartments.

Acknowledgments

I thank the NIH for supporting most of the cited work, and Uli von Andrian for comments on the manuscript.

References

Abbassi, O., Kishimoto, T.K., McIntire, L.V., Anderson, D.C., and Smith, C.W. (1993). *J. Clin. Invest.* **92,** 2719–2730.

Adams, D.H., Harvath, L., Bottaro, D.P., Interrante, R., Catalano, G., Tanaka, Y., Strain, A., Hubscher, S.G., and Shaw, S. (1994). *Proc. Natl. Acad. Sci. U.S.A.* **91,** 7144–7148.

Alam, R., Forsythe, P.A., Stafford, S., Lett-Brown, M.A., and Grant, J.A. (1992). *J. Exp. Med.* **176,** 781–786.

Albelda, S.M., Oliver, P.D., Romer, L.H., and Buck, C.A. (1990). *J. Cell Biol.* **110,** 1227–1237.

Albelda, S.M., Muller, W.A., Buck, C.A., and Newman, P.J. (1991). *J. Cell Biol.* **114,** 1059–1068.

Alon, R., Kassner, P.D., Carr, M.W., Finger, E.B., Hemler, M.E., and Springer, T.A. (1995). *J. Cell Biol.* (submitted).

Alon, R., Rossiter, H., Springer, T.A., and Kupper, T.S. (1995). *J. Cell Biol.* (in press).

Amatruda, T.T., Gerard, N.P., Gerard, C., and Simon, M.I. (1993). *J. Biol. Chem.* **268,** 10139–10144.

Anderson, A.O., and Anderson, N.D. (1976). *Immunology* **31,** 731–748.

Anderson, D.C., and Springer, T.A. (1987). *Ann. Rev. Med.* **38,** 175–194.

Arch, R., Wirth, K., Hofmann, M., Ponta, H., Matzku, S., Herrlich, P., and Zöller, M. (1992). *Science* **257,** 682–685.

Arfors, K.E., Lundberg, C., Lindborm, L., Lundberg, K., Beatty, P.G., and Harlan, J.M. (1987). *Blood* **69,** 338–340.

Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C.B., and Seed, B. (1990). *Cell* **61,** 1303–1313.

Baggiolini, M., Dewald, B., and Moser, B. (1994). *Adv. Immunol.* **55,** 97–179.

Barclay, A.N., Birkeland, M.L., Brown, M.H., Beyers, A.D., Davis, S.J., Somoza, C., and Williams, A.F. (1993). "The Leucocyte Antigen Facts Book." Academic Press, London.

Bargatze, R.F., Wu, N.W., Weissman, I.L., and Butcher, E.C. (1987). *J. Exp. Med.* **166,** 1125–1131.

Bargatze, R.F., Streeter, P.R., and Butcher, E.C. (1990). *J. Cell. Biochem.* **42,** 219–227.

Bargatze, R.F., and Butcher, E.C. (1993). *J. Exp. Med.* **178,** 367–372.

Baumhueter, S., Singer, M.S., Henzel, W., Hemmerich, S., Renz, M., Rosen, S.D., and Lasky, L.A. (1993). *Science* **262,** 436–438.

Beals, C.R., Wilson, C.B., and Perlmutter, R.M. (1987). *Proc. Natl. Acad. Sci. U.S.A.* **84,** 7886–7890.

Berg, E.L., Robinson, M.K., Mansson, O., Butcher, E.C., and Magnani, J.L. (1991a). *J. Biol. Chem.* **266,** 14869–14872.

Berg, E.L., Robinson, M.K., Warnock, R.A., and Butcher, E.C. (1991b). *J. Cell Biol.* **114,** 343–349.

Berg, E.L., Yoshino, T., Rott, L.S., Robinson, M.K., Warnock, R.A., Kishimoto, T.K., Picker, L.J., and Butcher, E.C. (1991c). *J. Exp. Med.* **174,** 1461–1466.

Berg, E.L., Magnani, J., Warnock, R.A., Robinson, M.K., and Butcher, E.C. (1992). *Biochem. Biophys. Res. Commun.* **184,** 1048–1055.

Berg, E.L., McEvoy, L.M., Berlin, C., Bargatze, R.F., and Butcher, E.C. (1993). *Nature* **366,** 695–698.

Berlin, C., Berg, E.L., Briskin, M.J., Andrew, D.P., Kilshaw, P.J., Holzmann, B., Weissman, I.L., Hamann, A., and Butcher, E.C. (1993). *Cell* **74,** 185–195.

Bevilacqua, M.P. (1993). *Annu. Rev. Immunol.* **11,** 767–804.

Bevilacqua, M.P., and Nelson, R.M. (1993). *J. Clin. Invest.* **91,** 379–387.

Bevilacqua, M.P., Pober, J.S., Mendrick, D.L., Cotran, R.S., and Gimbrone, M.A. (1987). *Proc. Natl. Acad. Sci. U.S.A.* **84,** 9238–9242.

Bienvenu, K., and Granger, D.N. (1993). *Am. J. Physiol.* **264,** H1504–H1508.

Bischoff, S.C., Krieger, M., Brunner, T., Rot, A., V. Tscharner, V., Baggiolini, M., and Dahinden, C.A. (1993). *Eur. J. Immunol.* **23,** 761–767.

Bjerknes, M., Cheng, H., and Ottaway, C.A. (1986). *Science* **231,** 402–405.

Bochner, B.S., Luscinskas, F.W., Gimbrone, M.A., Jr., Newman, W., Sterbinsky, S.A., Derse-Anthony, C.P., Klunk, D., and Schleimer, R.P. (1991). *J. Exp. Med.* **173,** 1553–1556.

Bradley, L.M., Atkins, G.G., and Swain, S.L. (1992). *J. Immunol.* **148,** 324–331.

Briscoe, D.M., Cotran, R.S., and Pober, J.S. (1992). *J. Immunol.* **14,** 2954–2960.

Briskin, M.J., McEvoy, L.M., and Butcher, E.C. (1993). *Nature* **363,** 461–464.

Buchanan, M.R., Crowley, C.A., Rosin, R.E., Gimbrone, M.A., and Babior, B.M. (1982). *Blood* **60,** 160–165.

Butcher, E.C. (1991). *Cell* **67,** 1033–1036.

Butcher, E.C., Scollay, R.G., and Weissman, I.L. (1980). *Eur. J. Immunol.* **10,** 556–561.

Buyon, J.P., Abramson, S.B., Philips, M.R., Slade, S.G., Ross, G.D., Weissman, G., and Winchester, R.J. (1988). *J. Immunol.* **140,** 3156–3160.

Cahill, R.N.P., Poskitt, D.C., Frost, H., and Trnka, Z. (1977). *J. Exp. Med.* **145,** 420–428.

Cahill, R.N.P., Poskitt, D.C., Hay, J.B., Heron, I., and Trnka, Z. (1979). *Eur. J. Immunol.* **9,** 251–253.

Camp, R.L., Scheynius, A., Johansson, C., and Puré, E. (1993). *J. Exp. Med.* **178,** 497–507.

Carlos, T.M., and Harlan, J.M. (1994). *Blood* (in press).

Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., and Springer, T.A. (1994). *Proc. Natl. Acad. Sci. U.S.A.* **91,** 3652–3656.

Carrell, N.A., Fitzgerald, L.A., Steiner, B., Erickson, H.P., and Phillips, D.R. (1985). *J. Biol. Chem.* **260,** 1743–1749.

Carter, S.B. (1967). *Nature* **213,** 256–260.

Cepek, K.L., Parker, C.M., Madara, J.L., and Brenner, M.B. (1993). *J. Immunol.* **150,** 3459–3470.

Cerf-Bensussan, N., Jarry, A., Brousse, N., Lisowska-Grospierre, B., Guy-Grand, D., and Griscelli, C. (1987). *Eur. J. Immunol.* **17,** 1279–1285.

Chaffin, K.E. and Perlmutter, R.M. (1991). *Eur. J. Immunol.* **21,** 2565–2573.

Chaffin, K.E., Beals, C.R., Wilkie, T.M., Forbush, K.A., Simon, M.I., and Perlmutter, R.M. (1990). *EMBO J.* **9,** 3821–3829.

Chan, P.-Y., Lawrence, M.B., Dustin, M.L., Ferguson, L.M., Golan, D.E., and Springer, T.A. (1991). *J. Cell Biol.* **115,** 245–255.

Chan, B.M.C., Elices, M.J., Murphy, E., and Hemler, M.E. (1992). *J. Biol. Chem.* **267,** 8366–8370.

Charo, I.F., Myers, S.J., Herman, A., Franci, C., Connolly, A.J., and Coughlin, S.R. (1994). *Proc. Natl. Acad. Sci. U.S.A.* **91,** 2752–2756.

Chisholm, P.L., Williams, C.A., and Lobb, R.R. (1993). *Eur. J. Immunol.* **23,** 682–688.

Cline, M.J. (1975). "The White Cell." Harvard University Press, Cambridge, Mass.

Coffman, R.L., Lebman, D.A., and Shrader, B. (1989). *J. Exp. Med* **170,** 1039–1044.

Cohnheim, J. (1889). "Lectures on General Pathology: A Handbook for Practitioners and Students." The New Sydenham Society, London.

Colditz, I.G. (1991). *In* "Vascular Endothelium: Interactions with Circulating Cells" (J.L. Gordon, ed.), pp. 175–187, Elsevier, New York.
Colditz, I.G. (1992). *In* "Animal Health and Production in the 21st Century" (K.J. Beh, ed.), CSIRO, Melbourne.
Colditz, I.G., and Movat, H.Z. (1984). *J. Immunol.* **133,** 2163–2168.
Colditz, I.G., and Watson, D.L. (1992). *Immunology* **272,** 278.
Cotran, R.S., Gimbrone, M.A., Jr., Bevilacqua, M.P., Mendrick, D.L., and Pober, J.S. (1986). *J. Exp. Med* **164,** 661–666.
Cross, A.H., and Raine, C.S. (1992). *Am. J. Pathol* **139,** 1401–1409.
Crowe, D.T., Chiu, H., Fong, S., and Weissman, I.L. (1993). *J. Cell Biol.* (submitted).
Culty, M., Miyake, K., Kincade, P.W., Sikorski, E., Butcher, E.C., and Underhill, C. (1990). *J. Cell Biol.* **111,** 2765–2774.
Cyster, J.G., Shotton, D.M., and Williams, A.F. (1991). *EMBO J.* **10,** 893–902.
Damle, N.K., Klussman, K., Dietsch, M.T., Mohagheghpour, N., and Aruffo, A. (1992). *Eur. J. Immunol.* **22,** 1789–1793.
deFougerolles, A.R., and Springer, T.A. (1992). *J. Exp. Med.* **175,** 185–190.
deFougerolles, A.R., Stacker, S.A., Schwarting, R., and Springer, T.A. (1991). *J. Exp. Med.* **174,** 253–267.
deFougeroles, A.R., Qin, X., and Springer, T.A. (1994). *J. Exp. Med.* **179,** 619–629.
Devreotes, P.N., and Zigmond, S.H. (1988). *Annu. Rev. Cell Biol.* **4,** 649–686.
Diamond, M.S., and Springer, T.A. (1993). *J. Cell Biol.* **120,** 545–556.
Diamond, M.S., and Springer, T.A. (1994). *Curr. Biol.* **4,** 506–517.
Diamond, M.S., Staunton, D.E., deFougerolles, A.R., Stacker, S.A., Garcia-Aguilar, J., Hibbs, M.L., and Springer, T.A. (1990). *J. Cell Biol.* **111,** 3129–3139.
Diamond, M.S., Staunton, D.E., Marlin, S.D., and Springer, T.A. (1991). *Cell* **65,** 961–971.
Diamond, M.S., Garcia-Aguilar, J., Bickford, J.K., Corbi, A.L., and Springer, T.A. (1993). *J. Cell Biol.* **120,** 1031–1043.
Dustin, M.L., and Springer, T.A. (1989). *Nature* **341,** 619–624.
Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E., and Lobb, R.R. (1990). *Cell* **60,** 577–584.
Erbe, D.V., Wolitzky, B.A., Presta, L.G., Norton, C.R., Ramos, R.J., Burns, D.K., Rumberger, J.M., Rao, B.N.N., Foxall, C., Brandley, B.K., and Lasky, L.A. (1992). *J. Cell. Biol.* **119,** 215–227.
Erlandsen, S.L., Hasslen, S.R., and Nelson, R.D. (1993). *J. Histochem. Cytochem.* **41,** 327–333.
Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M.L., Paulson, J.C., and Gershoni-Baruch, R. (1992). *N. Engl. J. Med.* **327,** 1789–1792.
Faull, R.J., Kovach, N.L., Harlan, H.M., and Ginsberg, M.H. (1994). *J. Exp. Med.* **179,** 1307–1316.
Fina, L., Molgaard, H.V., Robertson, D., Bradley, N.J., Monaghan, P., Delia, D., Sutherland, D.R., Baker, M.A., and Greaves, M.F. (1990). *Blood* **75,** 2417–2426.
Foxall, C., Watson, S.R., Dowbenko, D., Fennie, C., Lasky, L.A., Kiso, M., Hasegawa, A., Asa, D., and Brandley, B.K. (1992). *J. Cell Biol.* **117,** 895–902.
Fujimoto, T., Stroud, E., Whatley, R.E., Prescott, S.M., Muszbek, L., Laposata, M., and McEver, R.P. (1993). *J. Biol. Chem.* **268,** 11394–11400.
Gallatin, W.M., Weissman, I.L., and Butcher, E.C. (1983). *Nature* **304,** 30–34.

Geng, J.-G., Bevilacqua, M.P., Moore, K.L., McIntyre, T.M., Prescott, S.M., Kim, J.M., Bliss, G.A., Zimmerman, G.A., and McEver, R.P. (1990). *Nature* **343,** 757–760.

Gimbrone, M.A., Obin, M.S., Brock, A.F., Luis, E.A., Hass, P.E., Hebert, C.A., Yip, Y.K., Leung, D.W., Lowe, D.G., Kohr, W.J., Darbonne, W.C., Bechtol, K.B., and Baker, J.B. (1989). *Science* **246,** 1601–1603.

Ginsberg, M.H., Du, X., and Plow, E.F. (1992). *Curr. Opin. Cell Biol.* **4,** 766–771.

Graber, N., Gopal, T.V., Wilson, D., Beall, L.D., Polte, T., and Newman, W. (1990). *J. Immunol.* **145,** 819–830.

Granger, D.N., and Kubes, P. (1994). *J. Leukoc. Biol.* **55,** 662–675.

Graves, B.J., Crowther, R.L., Chandran, C., Rumberger, J.M., Li, S., Huang, K.-S., Presky, D.H., Familletti, P.C., Wolitzky, B.A., and Burns, D.K. (1994). *Nature* **367,** 532–538.

Günthert, U. (1993). *Curr. Top. Microbiol. Immunol.* **184,** 47–63.

Hamann, A., Westrich, D.J., Duijevstijn, A., Butcher, E.C., Baisch, H., Harder, R., and Thiele, H.G. (1988). *J. Immunol.* **140,** 693–699.

Hamann, A., Jablonski-Westrich, D., Jonas, P., and Thiele, H.-G. (1991). *Eur. J. Immunol.* **21,** 2925–2929.

Hamann, A., Andrew, D.P., Jablonski-Westrich, D., Holzmann, B., and Butcher, E.C. (1993). *J. Immunol.* **152,** 3282–3293.

Hammer, D.A., and Apte, S.M. (1992). *Biophys. J.* **63,** 35–57.

Harlan, J.M., Winn, R.K., Vedder, N.B., Doerschuk, C.M., and Rice, C.L. (1992). *In* "Adhesion: Its Role in Inflammatory Disease" (J.R. Harlan and D. Liu, eds.), pp. 117–150, W.H. Freeman & Co., New York.

Haynes, B.F., Liao, H.-X., and Patton, K.L. (1991). *Cancer Cells* **3,** 347–350.

Hechtman, D.H., Cybulsky, M.I., Fuchs, H.J., Baker, J.B., and Gimbrone, M.A., Jr. (1991). *J. Immunol.* **147,** 883–892.

Hemler, M.E. (1990). *Annu. Rev. Immunol.* **8,** 365–400.

Hemmerich, S., and Rosen, S.D. (1994). *Biochemistry* **33,** 4830–4835.

Hibbs, M.L., Jakes, S., Stacker, S.A., Wallace, R.W., and Springer, T.A. (1991a). *J. Exp. Med.* **174,** 1227–1238.

Hibbs, M.L., Xu, H., Stacker, S.A., and Springer, T.A. (1991b). *Science* **251,** 1611–1613.

Holzmann, B., and Weissman, I.L. (1989). *EMBO J.* **8,** 1735–1741.

Holzmann, B., McIntyre, B.W., and Weissman, I.L. (1989). *Cell* **56,** 37–46.

Hood, L., Huang, H.V., and Dreyer, W.J. (1987). *J. Supramol. Struc.* **7,** 531–559.

Horgan, K.J., Luce, G.E.G., Tanaka, Y., Schweighoffer, T. Shimizu, Y., Sharrow, S.O., and Shaw, S. (1992). *J. Immunol* **149,** 4082–4087.

Hu, M.C.-T., Crowe, D.T., Weissman, I.L., and Holzmann, B. (1992). *Proc. Natl. Acad. Sci. U.S.A.* **89,** 8254–8258.

Huber, A.R., Kunkel, S.L., Todd, R.F., III, and Weiss, S.J. (1991). *Science* **254,** 99–102.

Hynes, R.O. (1992). *Cell* **69,** 11–25.

Imai, Y., Singer, M.S., Fennie, C., Lasky, L.A., and Rosen, S.D. (1991). *J. Cell Biol* **113,** 1213–1221.

Imai, Y., Lasky, L.A., and Rosen, S.D. (1993). *Nature* **361,** 555–557.

Issekutz, T.B. (1991). *J. Immunol* **147,** 4178–4184.

Issekutz, T.B. (1992). *J. Immunol.* **149,** 3394–3402.

Issekutz,T.B. (1993). *Am. J. Pathol.* **143,** 1286–1293.

Issekutz, A.C., and Issekutz, T.B. (1993). *J. Immunol.* **151,** 2105–2115.

Issekutz, T.B., Chin, W., and Hay, J.B. (1982). *Immunology* **46,** 59–66.

Issekutz, T.B., Stoltz, J.M., and Meide, P.V.D. (1988). *J. Immunol.* **140,** 2989–2993.

Jalkanen, S., Bargatze, R.F., de los Toyos, J., and Butcher, E.C. (1987). *J. Cell Biol.* **105,** 983–993.

Janossy, G., Bofill, M., Rowe, D., Muir, J., and Beverley, P.C. (1989). *Immunology* **66,** 517–525.

Jung, T.M., Gallatin, W.M., Weissman, I.L., and Dailey, M.O. (1988). *J. Immunol.* **141,** 4110–4117.

Jutila, M.A., Lewinsohn, D., Berg, E.L., and Butcher, E. (1988). *In* "Leukocyte Adhesion Molecules" (T.A. Springer, D.C. Anderson, A.S. Rosenthal, and R. Rothlein, eds.) pp. 227–235, Springer-Verlag, New York.

Jutila, M.A., Rott, L., Berg, E.L., and Butcher, E.C. (1989). *J. Immunol.* **143,** 3318–3324.

Kameyoshi, Y., Dörschner, A., Mallet, A.I., Christophers, E., and Schröder, J.-M. (1992). *J. Exp. Med.* **176,** 587–592.

Kansas, G.S., Wood, G.S., Fishwild, D.M., and Engleman, E.G. (1985). *J. Immunol.* **134,** 2995–3002.

Kansas, G.S., Ley, K., Munro, J.M., and Tedder, T.F. (1993). *J. Exp. Med.* **177,** 833–838.

Keizer, G.D., Visser, W., Vliem, M., and Figdor, C.G. (1988). *J. Immunol.* **140,** 1393–1400.

Kilshaw, P.J., and Murant, S.J. (1990). *Eur. J. Immunol.* **20,** 2201–2207.

Kilshaw, P.J., and Murant, S.J. (1991). *Eur. J. Immunol.* **21,** 2591–2597.

Kinashi, T., St. Pierre, Y., Huang, C.-H., and Springer, T.A. (1993). *Blood* (submitted).

Kirchhausen, T., Staunton, D.E., and Springer, T.A. (1993). *J. Leukoc. Biol.* **53,** 342–346.

Kishimoto, T.K., O'Connor, K., Lee, A., Roberts, T.M., and Springer, T.A. (1987). *Cell* **48,** 681–690.

Kishimoto, T.K., Jutila, M.A., Berg, E.L., and Butcher, E.C. (1989a). *Science* **245,** 1238–1241.

Kishimoto, T.K., Larson, R.S., Corbi, A.L., Dustin, M.L., Staunton, D.E., and Springer, T.A. (1989b). *Adv. Immunol* **46,** 149–182.

Kishimoto, T.K., Warnock, R.A., Jutila, M.A., Butcher, E.C., Lane, C., Anderson, D.C., and Smith, C.W. (1991). *Blood* **78,** 805–811.

Kudo, C., Araki, A., Matsushima, K., and Sendo, F. (1991). *J. Immunol.* **174,** 2196–2201.

Kuna, P., Reddigari, S.R., Schall, T.J., Rucinski, D., Sadick, M., and Kaplan, A.P. (1993). *J. Immunol* **150,** 1932–1943.

Landis, R.C., Bennett, R.I., and Hogg, N. (1993). *J. Cell Biol* **120,** 1519–1527.

Larsen, C.G., Anderson, A.O., Appella, E., Oppenheim, J.J., and Matsushima, K. (1989a). *Science* **241,** 1464–1466.

Larsen, E., Celi, A., Gilbert, G.E., Furie, B.C., Erban, J.K., Bonfanti, R., Wagner, D.D., and Furie, B. (1989b). *Cell* **59,** 305–312.

Larsen, G.R., Sako, D., Ahern, T.J., Shaffer, M., Erban, J., Sajer, S.A., Gibson, R.M., Wagner, D.D., Furie, B.C., and Furie, B. (1992). *J. Biol. Chem.* **267,** 11104–11110.

Larson, R.S., Corbi, A.L., Berman, L., and Springer, T.A. (1989). *J. Cell Biol.* **108,** 703–712.

Lasky, L.A. (1992). *Science* **258,** 964–969.

Lasky, L.A., Singer, M.S., Dowbenko, D., Imai, Y., Henzel, W.J., Grimley, C., Fennie, C., Gillett, N., Watson, S.R., and Rosen, S.D. (1992). *Cell* **69,** 927–938.

Lawrence, M.B., and Springer, T.A. (1991). *Cell* **65,** 859–873.

Lawrence, M.B., and Springer, T.A. (1993). *J. Immunol* **151,** 6338–6346.
Lawrence, M.B., Smith, C.W., Eskin, S.G., and McIntire, L.V. (1990). *Blood* **75,** 227–237.
Lawrence, M.B., Bainton, D.F., and Springer, T.A. (1994). *Immunity* **1,** 137–145.
Leonard, E.J., and Yoshimura, T. (1990). *Immunol. Today* **11,** 97–101.
Leonard, E.J., Yoshimura, T., Tanaka, S., and Raffeld, M. (1991). *J. Invest. Dermatol.* **96,** 690–694.
Lewinsohn, D.M., Bargatze, R.F., and Butcher, E.C. (1987). *J. Immunol.* **138,** 4313–4321.
Ley, K., and Gaehtgens, P. (1991). *Circ. Res.* **69,** 1034–1041.
Ley, K., Gaehtgens, P., Fennie, C., Singer, M.S., Lasky, L.A., and Rosen, S.D. (1991). *Blood* **77,** 2553–2555.
Lo, S.K., Detmers, P.A., Levin, S.M., and Wright, S.D. (1989). *J. Exp. Med.* **169,** 1779–1793.
Lo, S.K., Lee, S., Ramos, R.A., Lobb, R., Rosa, M., Chi-Rosso, G., and Wright, S.D. (1991). *J. Exp. Med.* **173,** 1493–1500.
Loftus, J.C., O'Toole, T.E., Plow, E.F., Glass, A., Frelinger, A.L., III, and Ginsberg, M.H. (1990). *Science* **249,** 915–918.
Lollo, B.A., Chan, K.W.H., Hanson, E.M., Moy, V.T., and Brian, A.A. (1993). *J. Biol. Chem.* **268,** 1–8.
Lorant, D.E., Patel, K.D., McIntyre, T.M., McEver, R.P., Prescott, S.M., and Zimmerman, G.A. (1991). *J. Cell Biol.* **115,** 223–234.
Mackay, C.R. (1992). *Semin. Immunol.* **4,** 51–58.
Mackay, C.R. (1993). *Adv. Immunol.* **53,** 217–265.
Mackay, C.R., Marston, W.L., and Dudler, L. (1990). *J. Exp. Med.* **171,** 801–817.
Mackay, C.R., Marston, W., and Dudler, L. (1992a). *Eur. J. Immunol.* **22,** 2205–2210.
Mackay, C.R., Marston, W.L., Dudler, L., Spertini, O., Tedder, T.F., and Hein, W.R. (1992b). *Eur. J. Immunol.* **22,** 887–895.
Masinovsky, B., Urdal, D., and Gallatin, W.M. (1990). *J. Immunol.* **145,** 2886–2895.
Mayadas, T.N., Johnson, R.C., Rayburn, H., Hynes, R.O., and Wagner, D.D. (1993). *Cell* **74,** 541–554.
McCluskey, R.T., Benacerraf, B., and McClusky, J.W. (1963). *J. Immunol.* **90,** 466.
McEver, R.P. (1991). *Thromb. Haemost.* **65,** 223–228.
McEver, R.P., Beckstead, J.H., Moore, K.L., Marshall-Carlson, L., and Bainton, D.F. (1989). *J. Clin. Invest.* **84,** 92–99.
Mebius, R.E., Streeter, P.R., Breve, J., Duijvestijn, A.M., and Kraal, G. (1991). *J. Cell Biol.* **115,** 85–95.
Mebius, R.E., Dowbenko, D., Williams, A., Fennie, C., Lasky, L.A., and Watson, S.R. (1993). *J. Immunol.* **151,** 6769–6776.
Michishita, M., Videm, V., and Arnaout, M.A. (1993). *Cell* **72,** 857–867.
Miller, M.D., and Krangel, M.S. (1992). *Crit. Rev. Immunol.* **12,** 17–46.
Moore, K.L., Stultz, N.L., Diaz, S., Smith, D.F., Cummings, R.D., Varki, A., and McEver, R.P. (1992). *J. Cell Biol.* **118,** 445–456.
Moore, K.L., and Thompson, L.F. (1992). *Biochem. Biophys. Res. Commun.* **186,** 173–181.
Morse, S.I., and Barron, B.A. (1970). *J. Exp. Med.* **132,** 663–672.
Moy, P., Lobb, R., Tizard, R., Olson, D., and Hession, C. (1993). *J. Biol. Chem.* **268,** 8835–8841.
Muller, W.A., Ratti, C.M., McDonnell, S.L., and Cohn, Z.A. (1989). *J. Exp. Med.* **170,** 399–414.

Muller, W.A., Weigl, S.A., Deng, X., and Phillips, D.M. (1993). *J. Exp. Med.* **178,** 449–460.

Mulligan, M.S., Varani, J., Dame, M.K., Lane, C.L., Smith, C.W., Anderson, D.C., and Ward, P.A. (1991). *J. Clin. Invest.* **88,** 1396–1406.

Mulligan, M.S., Jones, M.L., Bolanowski, M.A., Baganoff, M.P., Deppeler, C.L., Meyers, D.M., Ryan, U.S., and Ward, P.A. (1993). *J. Immunol.* **150,** 5585–5595.

Murphy, P.M. (1994). *In* "Annual Review of Immunology" (W.E. Paul, C.G. Fathman, and H. Metzger, eds.), pp. 593–633, Annual Reviews, Inc., Palo Alto.

Nazziola, E., and House, S.D. (1992). *Microvasc. Res.* **44,** 127–142.

Nelson, R.M., Dolich, S., Aruffo, A., Cecconi, O., and Bevilacqua, M.P. (1993). *J. Clin. Invest.* **91,** 1157–1116.

Nermut, M.V., Green, N.M., Eason, P., Yamada, S.S., and Yamada, K.M. (1988). *EMBO J.* **7,** 4093–4099.

Newman, P.J., Berndt, M.C., Gorski, J., White, G.C., Lyman, S., Paddock, C., and Muller, W.A. (1990). *Science* **247,** 1219–1222.

Norgard, K.E., Moore, K.L., Diaz, S., Stults, N.L., Ushiyama, S., McEver, R.P., Cummings, R.D., and Varki, A. (1993). *J. Biol. Chem.* **268,** 12764–12774.

Nourshargh, S., and Williams, T.J. (1990). *J. Immunol.* **145,** 2633–2638.

Olofsson, A.M., Arfors, K.-E., Ramezani, L., Wolitzky, B.A., Butcher, E.C., and von Andrian, U.H. (1994). *Blood* (in press).

Oppenheimer-Marks, N., Davis, L.S., and Lipsky, P.E. (1990). *J. Immunol* **145,** 140–148.

Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G., and Lobb, R. (1989). *Cell* **59,** 1203–1211.

Osborn, L., Vassallo, C., and Benjamin, C.D. (1992). *J. Exp. Med.* **176,** 99–107.

Osborn, L., Vassallo, C., Browning, B.G., Tizard, R., Haskard, D.O., Benjamin, C.D., Douglas, I., and Kirchhausen, T. (1994). *J. Cell Biol.* **124,** 601–608.

Parker, C.M., Cepek, K., Russell, G.J., Shaw, S.K., Posnett, D., Schwarting, R., and Brenner, M.B. (1992). *Proc. Natl. Acad. Sci. U.S.A.* **89,** 1924–1928.

Parrott, D.M.V., and Wilkinson, P.C. (1981). *Prog. Allergy* **28,** 193–284.

Philips, M.R., Buyon, J.P., Winchester, R., Weissman, G., and Abramson, S.B. (1988). *J. Clin. Invest.* **82,** 495–501.

Picker, L.J., and Butcher, E.C. (1992). *Annu. Rev. Immunol.* **10,** 561–591.

Picker, L.J., Michie, S.A., Rott, L.S., and Butcher, E.C. (1990a). *Am. J. Pathol.* **136,** 1053–1068.

Picker, L.J., Terstappen, L.W.M.M., Rott, L.S., Streeter, P.R., Stein, H., and Butcher, E.C. (1990b). *J. Immunol.* **145,** 3247–3255.

Picker, L.J., Kishimoto, T.K., Smith, C.W., Warnock, R.A., and Butcher, E.C. (1991a). *Nature* **349,** 796–798.

Picker, L.J., Warnock, R.A., Burns, A.R., Doerschuk, C.M., Berg, E.L., and Butcher, E.C. (1991b). *Cell* **66,** 921–933.

Pircher, H., Groscurth, P., Baumhutter, S., Aguet, M., Zinkernagel, R.M., and Hengartner, H. (1986). *Eur. J. Immunol.* **16,** 172–181.

Pitzalis, C., Kingsley, G., Haskard, D., and Panayi, G. (1988). *Eur. J. Immunol.* **18,** 1397–1404.

Pober, J.S., and Cotran, R.S. (1990). *Physiol. Rev.* **70,** 427–452.

Pober, J.S., Doukas, J., Hughes, C.C.W., Savage, C.O.S., Munro, J.M., and Cotran, R.S. (1990). *Hum. Immunol.* **28,** 258–262.

Polte, T., Newman, W., and Gopal, T.V. (1990). *Nucleic Acids Res.* **18,** 5901.

Rosen, S.D. (1993). *Semin. Immunol.* **5,** 237–247.

Rot, A. (1992). *Immunol. Today* **13,** 291–294.

Rot, A., Krieger, M., Brunner, T., Bischoff, S.C., Schall, T.J., and Dahinden, C.A. (1992). *J. Exp. Med.* **176,** 1489–1495.

Roth, S.J., Carr, M.W., Rose, S.S., and Springer, T.A. (1994). *J. Immunol* (submitted).

Rothlein, R., Dustin, M.L., Marlin, S.D., and Springer, T.A. (1986). *J. Immunol.* **137,** 1270–1274.

Rüegg, C., Postigo, A.A., Sikorski, E.E., Butcher, E.C., Pytela, R., and Erle, D.J. (1992). *J. Cell Biol.* **117,** 179–189.

Sako, D., Chang, X.-J., Barone, K.M., Vachino, G., White, H.M., Shaw, G., Veldman, G.M., Bean, K.M., Ahern, T.J., Furie, B., Cumming, D.A., and Larsen, G.R. (1993). *Cell* **75,** 1179–1186.

San Gabriel-Masson, C. (1992). "Adhesion of Lymphocytes To The Lactating Mammary Gland In The Mouse," Ph.D. Thesis, Pennsylvania State University.

Schall, T.J. (1991). *Cytokine* **3,** 165–183.

Schall, T.J., Bacon, K., Toy, K.J., and Goeddel, D.V. (1990). *Nature* **347,** 669–671.

Schall, T.J., Bacon, K., Camp, R.D.R., Kaspari, J.W., and Goeddel, D.V. (1993). *J. Exp. Med.* **177,** 1821–1825.

Scheynius, A., Camp, R.L., and Puré, E. (1993). *J. Immunol.* **150,** 655–663.

Schmid-Schönbein, G.W., Usami, S., Skalak, R., and Chien, S. (1980). *Microvasc. Res.* **19,** 45–70.

Schweighoffer, T., Tanaka, Y., Tidswell, M., Erle, D.J., Horgan, K.J., Luce, G.E.G., Lazarovits, A.I., Buck, D., and Shaw, S. (1993). *J. Immunol.* **151,** 717–729.

Sekido, N., Mukaida, N., Harada, A., Nakanishi, I., Watanabe, Y., and Matsushima, K. (1993). *Nature* **365,** 654–657.

Sengelov, H., Kjeldsen, L., Diamond, M.S., Springer, T.A., and Borregaard, N. (1993). *J. Clin. Invest.* **92,** 1467–1476.

Shaw, S.K., Cepek, K.L., Murphy, E.A., Russell, G.J., Brenner, M.B., and Parker, C.M. (1994). *J. Biol. Chem.* **269,** 6016–6025.

Shimizu, Y., Shaw, S., Graber, N., Gopal, T.V., Horgan, K.J., Van Seventer, G.A., and Newman, W. (1991). *Nature* **349,** 799–802.

Shimizu, Y., Newman, W., Tanaka, Y., and Shaw, S. (1992). *Immunol. Today* **13,** 106–112.

Silber, A., Newman, W., Sasseville, V.G., Pauley, D., Beall, D., Walsh, D.G., and Ringler, D.J. (1994). *J. Clin. Invest.* **93,** 1554–1563.

Simmons, D., Makgoba, M.W., and Seed, B. (1988). *Nature* **331,** 624–627.

Simmons, D.L., Walker, C., Power, C., and Pigott, R. (1990). *J. Exp. Med.* **171,** 2147–2152.

Simmons, D.L., Satterthwaite, A.B., Tenen, D.G., and Seed, B. (1992). *J. Immunol.* **148,** 267–271.

Smith, C.W., Rothlein, R., Hughes, B.J., Mariscalco, M.M., Schmalstieg, F.C., and Anderson, D.C. (1988). *J. Clin. Invest.* **82,** 1746–1756.

Smith, C.W., Marlin, S.D., Rothlein, R., Toman, C., and Anderson, D.C. (1989). *J. Clin. Invest.* **83,** 2008–2017.

Smith, C.W., Kishimoto, T.K., Abbass, O., Hughes, B., Rothlein, R., McIntire, L.V., Butcher, E., and Anderson, D.C. (1991). *J. Clin. Invest.* **87,** 609–618.

Snyderman, R., and Uhing, R.J. (1992). *In* "Inflammation: Basic Principles and Clinical

Correlates" (J.I. Gallin, I.M. Goldstein, and R. Snyderman, eds.), pp. 421–439, Raven Press, New York.

Spangrude, G.J., Braaten, B.A., and Daynes, R.A. (1984). *J. Immunol.* **132,** 354–362.

Spangrude, G.J., Sacchi, F., Hill, H.R., Van Epps, D.E., and Daynes, R.A. (1985). *J. Immunol.* **135,** 4135–4143.

Spertini, O., Kansas, G.S., Munro, J.M., Griffin, J.D., and Tedder, T.F. (1991a). *Nature* **349,** 691–694.

Spertini, O., Luscinskas, F.W., Kansas, G.S., Munro, J.M., Griffin, J.D., Gimbrone, M.A., Jr., and Tedder, T.F. (1991b). *J. Immunol.* **147,** 2565–2573.

Spertini, O., Luscinskas, F.W., Gimbrone, M.A., Jr., and Tedder, T.F. (1992). *J. Exp. Med.* **175,** 1789–1792.

Springer, T.A. (1990a). *Nature* **346,** 425–433.

Springer, T.A. (1990b). *In* "Cell to Cell Interaction: a Karger Symposium" (M.M. Burger, B. Sordat, and R.M. Zinkernagel, eds. pp. 16–39, S. Karger AG, Basel.

Springer, T.A. (1994). *Cell* **76,** 301–314.

Stamper, H.B., Jr., and Woodruff, J.J. (1976). *J. Exp. Med.* **144,** 828.

Staunton, D.E., Marlin, S.D., Stratowa, C., Dustin, M.L., and Springer, T.A. (1988). *Cell* **52,** 925–933.

Staunton, D.E., Dustin, M.L., and Springer, T.A. (1989). *Nature* **339,** 61–64.

Staunton, D.E., Dustin, M.L., Erickson, H.P., and Springer, T.A. (1990). *Cell* **61,** 243–254.

Steininger, C.N., Eddy, C.A., Leimgruber, R.M., Mellors, A., and Welply, J.K. (1992). *Biochem. Biophys. Res. Commun.* **188,** 760–766.

Stevens, S.K., Weissman, I.L., and Butcher, E.C. (1982). *J. Immunol.* **2,** 844–851.

Stockinger, H., Gadd, S.J., Eher, R., Majdic, O., Schreiber, W., Kasinrerk, W., Strass, B., Schnabl, E., and Knapp, W. (1990). *J. Immunol.* **145,** 3889–3897.

Street, P.R., Lakey-Berg, E., Rouse, B.T.N., Bargatze, R.F., and Butcher, E.C. (1988a). *Nature* **331,** 41–46.

Streeter, P.R., Rouse, B.T.N., and Butcher, E.C. (1988b). *J. Cell Biol.* **107,** 1853–1862.

Sutherland, D.R., Marsh, J.C.W., Davidson, J., Baker, M.A., Keating, A., and Mellors, A. (1992). *Exp. Hematol.* **20,** 590–599.

Swerlick, R.A., Lee, K.H., Wick, T.M., and Lawley, T.J. (1992). *J. Immunol.* **148,** 78–83.

Takada, Y., Elices, M.J., Crouse, C., and Hemler, M.E. (1989). *EMBO J.* **8,** 1361–1368.

Tanaka, Y., Albelda, S.M., Horgan, K.J., Van Seventer, G.A., Shimizu, Y., Newman, W., Hallam, J., Newman, P.J., Buck, C.A., and Shaw, S. (1992). *J. Exp. Med.* **176,** 245–253.

Tanaka, Y., Adams, D.H., Hubscher, S., Hirano, H., Siebenlist, U., and Shaw, S. (1993). *Nature* **361,** 79–82.

Taub, D.D., Conlon, K., Lloyd, A.R., Oppenheim, J.J., and Kelvin, D.J. (1993a). *Science* **260,** 355–358.

Taub, D.D., Lloyd, A.R., Conlon, K., Wang, J.M., Ortaldo, J.R., Harada, A., Matsushima, K., Kelvin, D.J., and Oppenheim, J.J. (1993b). *J. Exp. Med.* **177,** 1809–1814.

Tedder, T.F., Matsuyama, T., Rothstein, D., Schlossman, S.F., and Morimoto, C. (1990). *Eur. J. Immunol.* **20,** 1351–1355.

Terry, R.W., Kwee, L., Levine, J.F., and Labow, M.A. (1993). *Proc. Natl. Acad. Sci. U.S.A.* **90,** 5919–5923.

Thornhill, M.H., Wellicome, S.M., Mahiouz, D.L., Lanchbury, J.S.S., Kyan-Aung, U., and Haskard, D.O. (1991). *J. Immunol.* **146,** 592–598.

Ushiyama, S., Laue, T.M., Moore, K.L., Erickson, H.P., and McEver, R.P. (1993). *J. Biol. Chem.* **268,** 15229–15237.

Van Ewijk, W., Brons, N.H.C., and Rozing, J. (1975). *Cell. Immunol.* **19,** 245–261.

Vedder, N.B., and Harlan, J.M. (1988). *J. Clin. Invest.* **81,** 676–682.

Villiger, P.M., Terkeltaub, R., and Lotz, M. (1992). *J. Immunol.* **149,** 722–727.

von Andrian, U.H., Chambers, J.D., McEvoy, L.M., Bargatze, R.F., Arfors, K.E., and Butcher, E.C. (1991). *Proc. Natl. Acad. Sci. U.S.A.* **88,** 7538–7542.

von Andrian, U.H., Hansell, P., Chambers, J.D., Berger, E.M., Filho, I.T., Butcher, E.C., and Arfors, K.E. (1992). *Am. J. Physiol.* **263,** H1034–H1044.

von Andrian, U.H., Berger, E.M., Ramezani, L., Chambers, J.D., Ochs, H.D., Harlan, J.M., Paulson, J.C., Etzioni, A., and Arfors, K.E. (1993a). *J. Clin. Invest.* **91,** 2893–2897.

von Andrian, U.H., Chambers, J.D., Berg, E.L., Michie, S.A., Brown, D.A., Karolak, D., Ramezani, L., Berger, E.M., Arfors, K.E., and Butcher, E.C. (1993b). *Blood* **82,** 182–191.

Vonderheide, R.H., and Springer, T.A. (1992). *J. Exp. Med.* **175,** 1433–1442.

Vonderheide, R.H., Tedder, T.F., Springer, T.A., and Staunton, D.E. (1994). *J. Cell Biol.* **125,** 215–222.

Walsh, L.J., Lavker, R.M., and Murphy, G.F. (1990). *Lab. Invest.* **63,** 592–600.

Wardlaw, A.C. and Parton, R. (1983). *Pharmacol. Ther.* **19,** 1–53.

Watson, S., Imai, Y., Fennie, C., Geoffroy, J.S., Rosen, S.D., and Lasky, L.A. (1990). *J. Cell Biol.* **110,** 2221–2229.

Watson, S.R., Fennie, C., and Lasky, L.A. (1991). *Nature* **349,** 164–167.

Wilkinson, P.C. (1982). "Chemotaxis and Inflammation." Churchill Livingstone, London.

Woodruff, J.J., Clarke, L.M., and Chin, Y.H. (1987). *Annu. Rev. Immunol.* **5,** 201–222.

Wright, S.D. and Meyer, B.C. (1986). *J. Immunol.* **136,** 1759–1764.

Wu, D., LaRosa, G.J., and Simon, M.I. (1993). *Science* **261,** 101–103.

Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L., and Karin, N. (1992). *Nature* **356,** 63–66.

Zhu, D., Cheng, C.-F., and Pauli, B.U. (1991). *Proc. Natl. Acad. Sci. U.S.A.* **88,** 9568–9572.

Zimmerman, G.A., Prescott, S.M., and McIntyre, T.M. (1992). *Immunol. Today* **13,** 93–100.